<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1072">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623242</url>
  </required_header>
  <id_info>
    <org_study_id>DIAN-TU-001 (gant-sola)</org_study_id>
    <secondary_id>The Alzheimer's Association</secondary_id>
    <secondary_id>U01AG042791</secondary_id>
    <secondary_id>2013-000307-17</secondary_id>
    <secondary_id>R01AG046179</secondary_id>
    <secondary_id>REec-2014-0817</secondary_id>
    <secondary_id>The Alzheimer's Association</secondary_id>
    <secondary_id>GHR Foundation</secondary_id>
    <secondary_id>Alzheimer's Association</secondary_id>
    <nct_id>NCT04623242</nct_id>
  </id_info>
  <brief_title>Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.</brief_title>
  <acronym>DIAN-TU</acronym>
  <official_title>A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alzheimer's Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Accelerating Medicines Partnership (AMP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, biomarker and cognitive&#xD;
      efficacy of investigational products in subjects who are known to have an Alzheimer's&#xD;
      disease-causing mutation by determining if treatment with the study drug slows the rate of&#xD;
      progression of cognitive impairment and improves disease-related biomarkers.&#xD;
&#xD;
      This is an analysis study for an MPRP: DIAN-TU-001 Master NCT01760005&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2) and amyloid precursor protein&#xD;
      (APP) that are associated with dominantly inherited Alzheimer's disease have very high&#xD;
      penetrance (near 100%). This study will target individuals who are either known to have a&#xD;
      disease-causing mutation or who are at risk for such a mutation (the child or sibling of a&#xD;
      proband with a known mutation) and unaware of their genetic status. Because the age at onset&#xD;
      of cognitive changes is relatively consistent within each family and with each mutation, an&#xD;
      age at onset is determined for each affected parent or mutation. This study will enroll&#xD;
      subjects who are either asymptomatic and are within a specific window of time of expected age&#xD;
      at onset for their family and/or mutation or who have symptoms of mild Alzheimer's disease.&#xD;
&#xD;
      The ability to identify individuals destined to develop Alzheimer's disease (AD) within the&#xD;
      next 10-15 years with a high degree of confidence provides a unique opportunity to assess the&#xD;
      efficacy of therapies while individuals are asymptomatic and/or very early stages of&#xD;
      dementia. Families with known disease-causing mutations are extremely rare and are&#xD;
      geographically dispersed throughout the world. These constraints necessitate a specialized&#xD;
      study design. Many of the subjects in this study will not yet have any cognitive symptoms of&#xD;
      AD; they will be &quot;asymptomatic&quot; carriers of mutations that cause dominantly inherited&#xD;
      Alzheimer's disease and would be expected to perform normally on standard cognitive and&#xD;
      functional testing. Imaging and fluid biomarkers will be used to demonstrate that the&#xD;
      treatment compounds have engaged their therapeutic targets. A set of cognitive measures&#xD;
      designed to assess the very earliest and most subtle cognitive changes will be collected.&#xD;
      Additionally, because many at-risk individuals decide not to know whether they have the&#xD;
      disease-associated mutation or not, some of the at-risk individuals enrolled in this study&#xD;
      will not have the disease causing mutations; they will be &quot;mutation negative&quot;. It is&#xD;
      important to enroll non-carrier subjects to avoid coercion (e.g., potential subjects may be&#xD;
      pressured into genetic testing to learn their genetic status in order to be eligible for the&#xD;
      trial). These mutation negative individuals will be assigned to the placebo group; and will&#xD;
      not be included in the primary efficacy or futility analyses. Subjects and site study staff&#xD;
      will remain blinded as to these individuals' active or placebo group assignment and mutation&#xD;
      status. Thus, the study will be double blinded for placebo and for mutation status, except&#xD;
      for mutation positive subjects who are aware of their genetic status. There may be&#xD;
      exceptional circumstances when required by local regulation or health authorities where&#xD;
      enrollment may be restricted to mutation carriers only but such mandates will be thoroughly&#xD;
      documented and agreed upon by the governing regulatory agency and sponsor. Several different&#xD;
      therapies (each referred to as a study drug arm) will be tested in order to increase the&#xD;
      likelihood that an effective treatment will be discovered. The compounds are selected for&#xD;
      this trial based on mechanism of action and available data on efficacy and safety profile.&#xD;
&#xD;
      The study design includes a pooled placebo group shared by all study drug arms. Mutation&#xD;
      positive subjects will be assigned to a study drug arm and subsequently randomized within&#xD;
      that arm in an overall 3:1 ratio to active drug:placebo. Mutation negative subjects will all&#xD;
      receive placebo treatment. Importantly, subjects and study staff will not be blinded as to&#xD;
      which study drug arm (gantenerumab or solanezumab) each subject has been assigned; they will&#xD;
      be blinded as to whether subjects have been randomized to active drug or placebo. Biomarker&#xD;
      data will be analyzed for pre-specified endpoints consistent with the drug's mechanism of&#xD;
      action and known effects on the tested biomarkers. The primary cognitive endpoint will be the&#xD;
      same for all study drug arms. This study is an adaptive platform based study. Interim&#xD;
      analyses of the imaging or fluid biomarker endpoint will assess safety and whether each study&#xD;
      drug engages its biological targets. This biomarker approach is particularly important in&#xD;
      this study as most study subjects will be cognitively normal at baseline and most will remain&#xD;
      cognitively normal during the first 2 years of the study. The cognitive composite is designed&#xD;
      to assess subtle cognitive changes that may be detectable before the onset of dementia. The&#xD;
      cognitive multivariate disease progression model (MDPM) endpoint design will allow for&#xD;
      detection of these subtle cognitive changes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2012</start_date>
  <completion_date type="Actual">March 6, 2020</completion_date>
  <primary_completion_date type="Actual">November 22, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Interventional</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess Cognitive Efficacy in Individuals With Mutations Causing Dominantly Inherited AD as Measured by the DIAN-Multivariate Cognitive Endpoint (DIAN-MCE);</measure>
    <time_frame>Baseline through Week 260</time_frame>
    <description>Multivariate Disease Progression Model adjusted for Estimated Years to Onset (EYO)and includes all timepoints up to treatment discontinuation. The treatment effect is reported relative to the mutation positive placebo arm.&#xD;
Multivariate Cognitive Endpoint comprising: (i) Wechsler Memory Scale-Revised Logical Memory Delayed Recall Test (MEMUNITS), (ii) Wechsler Adult Intelligence Scale Digit Symbol Substitution Test (WAIS), (iii) Mini-Mental State Examination (MMSE), and (iv) International Shopping List Task (ISLT). Measurements for each test were normalized using the mean (SD) at DIAN-TU-001 baseline for mutation negative subjects. Higher scores indicate more favourable cognitive performance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gantenerumab: Rate of Change Over Time- Clinical Dementia Rating Sum of Boxes (CDR-SB)</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>CDR-SB score is considered a more detailed quantitative general index of cognition and function, and provides more information than the global CDR score in patients with mild dementia&#xD;
Scores range from 0-18 with lower scores showing more favorable cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gantenerumab: Rate of Change Over Time- Functional Assessment Scale (FAS)</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>The Functional Assessment Scale is to be administered and completed by the study partner about subjects for whom they care. This scale measures instrumental activities of daily living such as preparing balanced meals and managing personal finances. The intent of the FAS is to assess change in an individual's functional activities, relative to previously attained abilities, that are caused by cognitive dysfunction. If the study partner indicates that the subject no longer performs a particular task, it is reasonable to probe further and ask if they think the subject could still do the task. This will help tease out the relevant cognitive impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gantenerumab: Imaging Measures Composite [11C] PiB Partial Volume Corrected Regional Spread Function Standardized Uptake Value Ratio - Composite</measure>
    <time_frame>Baseline, Weeks 52, 104 and 208</time_frame>
    <description>In vivo quantification of β-amyloid deposition using positron emission tomography. This measure is a composite of brain regions. Higher scores indicate worse disease stage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Clinical Measures- Clinical Dementia Rating (CDR)</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, and 208</time_frame>
    <description>Clinical Dementia Rating - Global Score - Number of Subjects with an Increase from Baseline by Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Clinical Measures- CDR Sum of Boxes (CDR-SB)</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, and 208</time_frame>
    <description>CDR-SB score is considered a more detailed quantitative general index and provides more information than the global CDR score in patients with mild dementia&#xD;
Scores range from 0-18 with lower scores showing more favorable cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Clinical Measures- Geriatric Depression Scale (GDS)</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>The Geriatric Depression Scale (GDS) is a self-report measure of depression in older adults. Users respond in a &quot;Yes/No&quot; format. Of the 15 items, 10 indicate the presence of depression when answered positively while the other 5 are indicative of depression when answered negatively.&#xD;
Scores range from 0-15 for completed questionnaires. A score of 88 is recorded for participants unable to complete the test.&#xD;
Lower scores show more favorable outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Clinical Measures- Neuropsychiatric Inventory Questionnaire (NPI-Q)</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>The questionnaire is to be administered and completed by the study partner about patients for whom they care. Each of the 12 NPI-Q domains contains a survey question that reflects cardinal symptoms of that domain. Initial responses to each domain question are &quot;Yes&quot;(present) or &quot;No&quot; (absent). If the response to the domain question is &quot;No&quot;, the study partner goes to the next question. If &quot;Yes&quot;, the study partner then rates both the Severity of the symptoms present within the last month on a 3-point scale and the associated impact of the symptom manifestations on them (i.e. Caregiver Distress) using a 5-point scale. The NPI-Q provides symptom 'Severity' and 'Distress' ratings for each symptom reported, and total 'Severity' and 'Distress' scores reflecting the sum of individual domain scores.&#xD;
Scores range from 0-36 with lower scores indicating more favorable cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Clinical Measures- Functional Assessment Scale (FAS)</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>The Functional Assessment Scale is to be administered and completed by the study partner about subjects for whom they care. This scale measures instrumental activities of daily living such as preparing balanced meals and managing personal finances. The intent of the FAS is to assess change in an individual's functional activities, relative to previously attained abilities, that are caused by cognitive dysfunction. If the study partner indicates that the subject no longer performs a particular task, it is reasonable to probe further and ask if they think the subject could still do the task. This will help tease out the relevant cognitive impairment&#xD;
Scores range from 0-30 with lower scores indicate more favorable cognitive performance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Clinical Measures- Mini-Mental Status State Examination (MMSE)</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>MMSE is a brief, quantitative measure of cognitive status in adults used to screen for cognitive impairment, to estimate the severity of cognitive impairment at a given point in time, to follow the course of cognitive changes in an individual over time, and to document an individual's response to treatment.&#xD;
Scores range from 0-30 and higher scores indicate more favorable cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Cognitive Measures- International Shopping List Task 30-Minute Delayed Recall</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>Classic list-learning test that measures verbal learning &amp; memory.&#xD;
Scores range from 0-12 with higher scores indicating more favorable cognitive performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Cognitive Measures- Groton Maze Learning Test 30 Minute Delayed Recall</measure>
    <time_frame>Baseline, Week 52, 104, 156, 208 and 260</time_frame>
    <description>The Groton Maze Learning Test 30 minute delayed recall measures episodic memory. The primary outcome is the number of errors made during recall of the previously memorized pathway from the Groton Maze Learning Test. The minimum score is 0 errors and the max is 999. Lower scores indicate better cognitive performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Cognitive Measures- Groton Maze Learning Test Delayed Reversed Recall</measure>
    <time_frame>Baseline, Week 52, 104, 156, 208 and 260</time_frame>
    <description>The Groton Maze Learning Test measures executive function using a maze learning paradigm. A 10 x 10 grid of tiles is presented to the participant on the screen. A 28-step pathway is hidden among these tiles. A blue tile indicates the start and a tile with red circles indicates the finish. The participant must move one step at a time from the start toward the end by touching a tile next to their current location. If the correct move is made a green checkmark appears and if the move is incorrect a red cross is revealed. Once completed, they are returned to the start location to repeat the test and must try to remember the pathway they have just completed. &quot;Delayed Reverse Recall&quot; measures spatial working memory.&#xD;
The outcome is the number of errors made with the range of 0-999. Lower scores indicate better cognitive performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Cognitive Measures- Trailmaking Test Part A</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>Trail Making test taps attention, processing speed, and executive function. Part A consists of 25 circles numbered 1 through 25 distributed over a white sheet of standard document-sized paper. The subject is instructed to connect the circles with a drawn line as quickly as possible in ascending numerical order without lifting their pen.&#xD;
The subject's performance is judged in terms of the time, in seconds, required to complete each trail (Max time 150 seconds). Lower scores indicate more favorable cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Cognitive Measures- Trailmaking Test Part B</measure>
    <time_frame>Baseline, Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>This test taps attention, processing speed, and executive function and depends on visuo-motor and perceptual-scanning skills and also requires considerable cognitive flexibility in shifting from number to letter sets under time pressure. Part B consists of 25 circles, but these circles contain either numbers (1 through 13) or letters (A through L). The subject must connect the circles while alternating between numbers and letters in an ascending order (e.g., A to 1; 1 to B; B to 2; 2 to C).&#xD;
The subject's performance is judged in terms of the time, in seconds, required to complete each Trail (Max of 300 seconds). Lower scores indicate more favorable cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Cognitive Measures- WAIS-R Digit-Symbol Substitution Test</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>This test engages multiple cognitive abilities, including attention, psychomotor speed, complex scanning, visual tracking, and immediate memory.&#xD;
Scores range from 0-93 with higher scores indicate more favorable cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Cognitive Measures- WMS-R Digit Span Backward</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>Widely used measure of working memory (or attention) in which the subject is read number sequences of increasing length and then asked to repeat each sequence backward. The primary measure of performance is the number of digit sequences correctly reversed.&#xD;
The unit of measure is number of digit sequences correctly recalled and ranges from 0-12. Higher scores indicate more favorable cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Cognitive Measures- WMS-R Digit Span Forward</measure>
    <time_frame>Baseline, Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>This is a widely-used test of working memory in which the subject is read number sequences of increasing length and asked to repeat them. The total score is the number of sequences correctly repeated.&#xD;
The unit of measure is number of digit sequences correctly recalled and ranges from 0-12. Higher scores indicate more favorable cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Cognitive Measures- Raven's Progressive Matrices (Set A)</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>This is a measure of fluid intelligence. This test is used to get an estimate of the subjects IQ at baseline. Subjects are asked to complete a visual pattern by circling one of six response choices.&#xD;
Scores range from 0-12 with higher scores indicating more favorable cognitive performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Cognitive Measures- Category Fluency (Animals)</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>Category Fluency is a widely used measure of semantic memory (verbal fluency, language). The subject is asked to name different exemplars of a given semantic category (animals), and the number of unique exemplars named is scored.&#xD;
Higher scores indicate more favorable cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Cognitive Measures- Category Fluency (Vegetables)</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>Category Fluency is a widely used measure of semantic memory (verbal fluency, language). The subject is asked to name different exemplars of a given semantic category (vegetables), and the number of unique exemplars named is scored.&#xD;
Higher scores indicate more favorable cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Cognitive Measures- WMS-R Logical Memory Delayed Recall Test</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>Measure of delayed recall (episodic memory) of a story read to the subject at the beginning of the testing session and subject is asked to relay the story 20 minutes later.&#xD;
Scores range from 0-25 with higher scores indicating more favorable cognitive performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Cognitive Measures- WMS-R Logical Memory Immediate Recall Test</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>This test assesses the ability to recall a short story. The subject is read a short story and immediately after hearing the story, the subject is asked to retell the story from memory.&#xD;
Scores range from 0-25 with higher scores indicating more favorable cognitive performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Cognitive Measures- Composite Including: Alternative Multivariate Composite: (1) Digit Span Backwards; (2) Logical Memory (Immediate); (3) Trailmaking B; (4) Category Fluency (Animals)</measure>
    <time_frame>Baseline through Week 260</time_frame>
    <description>Multivariate Disease Progression Model adjusted for estimated years from symptom onset (EYO) and includes all time points up to treatment discontinuation. The treatment effect for Solanezumab is reported relative to the mutation positive placebo arm.&#xD;
This alternative multivariate endpoint includes four tests: Logical Memory Immediate Recall, Digit Span Backward Recall, Category Fluency (Animals), Trailmaking Test Part B. Measurements for each test will be normalized using the mean (SD) at DIAN-TU-001 baseline among mutation negative subjects before being analyzed. For the Trailmaking Test B, the scores will be multiplied by -1 as higher scores indicate worse performance; whereas for the other three, lower scores indicate worse performance. Therefore, on the standardized endpoints, lower scores indicate worse performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Imaging Measures- Brain Amyloid Load as Measured by [11C]PiB-PET Non-partial Volume Corrected</measure>
    <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
    <description>PiB Standardized Uptake Value Ratio ([11C]PiB SUVR) is the most common quantitative method used to make regional comparisons within a subject as well as between subjects and computed as the degree of radiotracer uptake in a target region of interest (regions dervived via automated segmentation using FreeSurfer) with respect to a reference region. In amyloid and tau imaging, SUVR is typically generated using some portion or the entire cerebellum as a reference because cerebellum is not affected until late in the progression of AD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Imaging Measures- Brain Amyloid Load as Measured by Florbetapir PET</measure>
    <time_frame>Weeks104 and 208</time_frame>
    <description>Florbetapir Standardized Uptake Value Ratio ([18F]AV-45 SUVR) is the most common quantitative method used to make regional comparisons within a subject as well as between subjects and computed as the degree of radiotracer uptake in a target region of interest (regions derivved via automated segmentation using FreeSurfer) with respect to a reference region. In amyloid and tau imaging, SUVR is typically generated using some portion or the entire cerebellum as a reference because cerebellum is not affected until late in the progression of AD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Imaging Measures- Brain Glucose Metabolism as Measured by Fluorodeoxyglucose (FDG)-PET Non-partial Volume Corrected</measure>
    <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
    <description>FDG Standardized Uptake Value Ratio ([18F]FDG SUVR) is the most common quantitative method used to make regional comparisons within a subject as well as between subjects and computed as the degree of radiotracer uptake in a target region of interest (regions derivved via automated segmentation using FreeSurfer) with respect to a reference region. In amyloid and tau imaging, SUVR is typically generated using some portion or the entire cerebellum as a reference because cerebellum is not affected until late in the progression of AD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Imaging Measures- Brain Atrophy as Measured by Cortical Thickness of Regions of Interest - Precuneus Region</measure>
    <time_frame>Baseline and Weeks 52, 104, 156 and 208</time_frame>
    <description>Brain atrophy was defined by structural magnetic resonance imaging (MRI) A Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequence was processed using the Freesurfer software suite. This package provides volumes and thickness values for cortical regions and volumes for subcortical regions. For the clinical trial we examined cortical thickness values in prespecified regions of interest known to show atrophy in autosomal dominant Alzheimer Disease. Higher measurements are more favorable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Imaging Measures- Volumetric MRI Combined Total Volume Corrected for Head Size - Hippocampus Volume</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>Brain atrophy was defined by structural magnetic resonance imaging (MRI) A Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequence was processed using the Freesurfer software suite. This package provides volumes and thickness values for cortical regions and volumes for subcortical regions. For the clinical trial we examined volume values in prespecified regions of interest known to show atrophy in autosomal dominant Alzheimer Disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Imaging Measures- Brain Tau Load as Measured by Flortaucipir PET Non-partial Volume Corrected</measure>
    <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
    <description>This variable represents how much neurofibrillary tau pathology is present in brain as assessed using positron emission tomography (PET). Scans were conducted using [F18] Flortaucipir, a commonly used tracer in the field.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Imaging Measures- Brain Atrophy as Measured by Whole Brain Volume Corrected for Head Size</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>Brain atrophy was defined by structural magnetic resonance imaging (MRI) A Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequence was processed using the Freesurfer software suite. This package provides volumes and thickness values for cortical regions and volumes for subcortical regions. A whole brain volume measure was generated to represent global atrophy across the cortical and subcortical regions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Imaging Measures- Brain Atrophy as Measured by Ventricular Volume (Volumetric MRI) Corrected for Head Size</measure>
    <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
    <description>Rather than looking at how tissue in the brain changes, it is also possible to quantify how the ventricles, fluid filled spaces in the brain, change. Increasing ventricular volume represents greater amounts of cerebral spinal fluid which suggests atrophy of the brain. Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequences were processed using the Freesurfer software suite. Total ventricular volume was calculated from the ventricular volumes generated by this program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Fluid Biomarker Measures- CSF Aβ 40 Free Change From Baseline</measure>
    <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
    <description>Measured concentration of the drug bound and free soluble Aβ1-40 peptide in cerebrospinal fluid using enzyme-linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Fluid Biomarker Measures- CSF Aβ 42 Free</measure>
    <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
    <description>Measured concentration of the total soluble Aβ 1-42 peptide in cerebrospinal fluid using ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Fluid Biomarker Measures- CSF Tau</measure>
    <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
    <description>Measured concentration of the soluble Tau peptide in cerebrospinal fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Fluid Biomarker Measures- CSF pTau 181</measure>
    <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
    <description>Measured concentration of phosphorylated tau at threonine-181 in cerebrospinal fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Change From Baseline Fluid Biomarker Measures- CSF Neurofilament Light Chain (NfL)</measure>
    <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
    <description>Measured concentration of neurofilament light chain in cerebrospinal fluid using SIMO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Fluid Biomarker Measures- Plasma Neurofilament Light Chain (NfL)</measure>
    <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
    <description>Measured concentration of neurofilamnet light chain in plasma using Single Molecule Array (SIMOA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Fluid Biomarker Measures- Plasma Anti-drug Antibodies (ADA)</measure>
    <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
    <description>Measurement of the presence or absence of anti-drug antibodies in serum&#xD;
Note: Mutation Negative Placebo subjects are not displayed as anti-drug antibody testing was not to be evaluated for these subjects.&#xD;
Note: Treatment Emergent Anti-Drug Antibody Positive subjects are defined as those with either (a) a baseline status of ADA Not Present and at least one post-baseline ADA present with a titer &gt;= 1:20 or (b) both a baseline and post-baseline status of ADA Present with the post-baseline titer being 2 dilutions (4-fold) greater than the baseline titer.&#xD;
Note: Treatment Emergent Anti-Drug Antibody Inconclusive subjects are defined as those for whom &gt;=20% of the subject's post-baseline ADA results are ADA Inconclusive and all remaining post-baseline samples are ADA Not Present.&#xD;
Note: Treatment Emergent Anti-Drug Antibody Negative subjects are defined as those who are evaluable for TE ADA but are neither TE ADA Positive nor TE ADA Inconclusive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Fluid Biomarker Measures- Total Plasma Aβ 1-40</measure>
    <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
    <description>Measured concentration of the total soluble Aβ 1-40 peptide in cerebrospinal fluid using ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Fluid Biomarker Measures- Total Plasma Aβ 42</measure>
    <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
    <description>Measured concentration of the total soluble Aβ 1-42 peptide in cerebrospinal fluid using ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Fluid Biomarker Measures- CSF Aβ 42 Total</measure>
    <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
    <description>Measured concentration of the total soluble Aβ1-42 peptide in cerebrospinal fluid using enzyme-linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solanezumab: Fluid Biomarker Measures- CSF Aβ 40 Total</measure>
    <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
    <description>Measured concentration of the total soluble Aβ1-40 peptide in cerebrospinal fluid using enzyme-linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Alzheimers Disease</condition>
  <condition>Dementia</condition>
  <condition>Alzheimers Disease, Familial</condition>
  <arm_group>
    <arm_group_label>Gantenerumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Solanezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo (Gantenerumab)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo (Solanezumab)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gantenerumab</intervention_name>
    <description>Subcutaneously every 4 weeks at escalating doses</description>
    <arm_group_label>Gantenerumab</arm_group_label>
    <other_name>RO4909832</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solanezumab</intervention_name>
    <description>Intravenous infusion every 4 weeks at escalating doses</description>
    <arm_group_label>Solanezumab</arm_group_label>
    <other_name>LY2062430</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo (Gantenerumab)</intervention_name>
    <description>Subcutaneous injection of placebo every 4 weeks</description>
    <arm_group_label>Matching placebo (Gantenerumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo (Solanezumab)</intervention_name>
    <description>Intravenous infusion of placebo every 4 weeks</description>
    <arm_group_label>Matching Placebo (Solanezumab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between 18-80 years of age&#xD;
&#xD;
          -  Individuals who know they have an Alzheimer's disease-causing mutation or are unaware&#xD;
             of their genetic status and have dominantly inherited Alzheimer's disease (DIAD)&#xD;
             mutation in their family.&#xD;
&#xD;
          -  Are within -15 to + 10 years of the predicted or actual age of cognitive symptom&#xD;
             onset.&#xD;
&#xD;
          -  Cognitively normal or with mild cognitive impairment or mild dementia, Clinical&#xD;
             Dementia Rating (CDR) of 0-1 (inclusive)&#xD;
&#xD;
          -  Fluency in DIAN-TU trial approved language and evidence of adequate premorbid&#xD;
             intellectual functioning&#xD;
&#xD;
          -  Able to undergo Magnetic Resonance Imaging (MRI), Lumbar Puncture (LP), Positron&#xD;
             Emission Tomography (PET), and complete all study related testing and evaluations.&#xD;
&#xD;
          -  For women of childbearing potential, if partner is not sterilized, subject must agree&#xD;
             to use effective contraceptive measures (hormonal contraception, intra-uterine device,&#xD;
             sexual abstinence, barrier method with spermicide).&#xD;
&#xD;
          -  Adequate visual and auditory abilities to perform all aspects of the cognitive and&#xD;
             functional assessments.&#xD;
&#xD;
          -  Has a Study Partner who in the investigator's judgment is able to provide accurate&#xD;
             information as to the subject's cognitive and functional abilities, who agrees to&#xD;
             provide information at the study visits which require informant input for scale&#xD;
             completion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of brain MRI scans indicative of any other significant abnormality&#xD;
&#xD;
          -  Alcohol or drug dependence currently or within the past 1 year&#xD;
&#xD;
          -  Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or&#xD;
             foreign metal objects in the eyes, skin or body which would preclude MRI scan.&#xD;
&#xD;
          -  History or presence of clinically significant cardiovascular disease, hepatic/renal&#xD;
             disorders, infectious disease or immune disorder, or metabolic/endocrine disorders&#xD;
&#xD;
          -  Anticoagulants except low dose (≤ 325 mg) aspirin.&#xD;
&#xD;
          -  Have been exposed to a monoclonal antibody targeting beta amyloid peptide within the&#xD;
             past six months.&#xD;
&#xD;
          -  History of cancer within the last 5 years, except basal cell carcinoma, non-squamous&#xD;
             skin carcinoma, prostate cancer or carcinoma in situ with no significant progression&#xD;
             over the past 2 years.&#xD;
&#xD;
          -  Positive urine or serum pregnancy test or plans or desires to become pregnant during&#xD;
             the course of the trial.&#xD;
&#xD;
          -  Subjects unable to complete all study related testing, including implanted metal that&#xD;
             cannot be removed for MRI scanning, required anticoagulation and pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall J Bateman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama in Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuroscience Research Australia</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mental Health Research Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The McCuster Foundation of Alzheimer's Disease Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UBC Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill Center for Studies in Aging</name>
      <address>
        <city>Verdun</city>
        <state>Quebec</state>
        <zip>H4H 1R3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <state>Haute Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Roger Salengro - CHU Lille</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitie-Salpetriere</name>
      <address>
        <city>Paris cedex 13</city>
        <state>Paris</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Neurologique Pierre Wertheimer</name>
      <address>
        <city>Bron cedex</city>
        <state>Rhone</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen - Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <state>Seine Maritime</state>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico, School of Medicine</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The National Hospital for Neurology and Neurosurgery</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>WC1B 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.dianexr.org/</url>
    <description>Expanded registry</description>
  </link>
  <reference>
    <citation>Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012 Aug 30;367(9):795-804. doi: 10.1056/NEJMoa1202753. Epub 2012 Jul 11. Erratum in: N Engl J Med. 2012 Aug 23;367(8):780.</citation>
    <PMID>22784036</PMID>
  </reference>
  <reference>
    <citation>Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012 Jul;8(4):261-71. doi: 10.1016/j.jalz.2011.09.224. Epub 2012 Jun 5.</citation>
    <PMID>22672770</PMID>
  </reference>
  <reference>
    <citation>Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, Fanning K, Farlow MR, Hassenstab J, McDade EM, Mills S, Paumier K, Quintana M, Salloway SP, Santacruz A, Schneider LS, Wang G, Xiong C; DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network. The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement. 2017 Jan;13(1):8-19. doi: 10.1016/j.jalz.2016.07.005. Epub 2016 Aug 29.</citation>
    <PMID>27583651</PMID>
  </reference>
  <reference>
    <citation>Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, Althage MC, Belyew S, Benzinger TL, Brooks WS, Buckles VD, Cairns NJ, Clifford D, Danek A, Fagan AM, Farlow M, Fox N, Ghetti B, Goate AM, Heinrichs D, Hornbeck R, Jack C, Jucker M, Klunk WE, Marcus DS, Martins RN, Masters CM, Mayeux R, McDade E, Morris JC, Oliver A, Ringman JM, Rossor MN, Salloway S, Schofield PR, Snider J, Snyder P, Sperling RA, Stewart C, Thomas RG, Xiong C, Bateman RJ. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris). 2013 Oct;169(10):737-43. doi: 10.1016/j.neurol.2013.07.017. Epub 2013 Sep 6. Review.</citation>
    <PMID>24016464</PMID>
  </reference>
  <reference>
    <citation>Wang G, Berry S, Xiong C, Hassenstab J, Quintana M, McDade EM, Delmar P, Vestrucci M, Sethuraman G, Bateman RJ; Dominantly Inherited Alzheimer Network Trials Unit. A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease. Stat Med. 2018 Sep 20;37(21):3047-3055. doi: 10.1002/sim.7811. Epub 2018 May 14.</citation>
    <PMID>29761523</PMID>
  </reference>
  <reference>
    <citation>Weninger S, Carrillo MC, Dunn B, Aisen PS, Bateman RJ, Kotz JD, Langbaum JB, Mills SL, Reiman EM, Sperling R, Santacruz AM, Tariot PN, Welsh-Bohmer KA. Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. Alzheimers Dement. 2016 May;12(5):631-2. doi: 10.1016/j.jalz.2016.04.001.</citation>
    <PMID>27157073</PMID>
  </reference>
  <reference>
    <citation>Grill JD, Bateman RJ, Buckles V, Oliver A, Morris JC, Masters CL, Klunk WE, Ringman JM; Dominantly Inherited Alzheimer's Network. A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease. Alzheimers Res Ther. 2015 Jul 22;7(1):50. doi: 10.1186/s13195-015-0135-0. eCollection 2015.</citation>
    <PMID>26203303</PMID>
  </reference>
  <reference>
    <citation>McDade E, Bateman RJ. Stop Alzheimer's before it starts. Nature. 2017 Jul 12;547(7662):153-155. doi: 10.1038/547153a.</citation>
    <PMID>28703214</PMID>
  </reference>
  <reference>
    <citation>McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, Berman SB, Klunk W, Noble J, Ringman J, Ghetti B, Farlow M, Sperling RA, Chhatwal J, Salloway S, Graff-Radford NR, Schofield PR, Masters C, Rossor MN, Fox NC, Levin J, Jucker M, Bateman RJ; Dominantly Inherited Alzheimer Network. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. 2018 Oct 2;91(14):e1295-e1306. doi: 10.1212/WNL.0000000000006277. Epub 2018 Sep 14.</citation>
    <PMID>30217935</PMID>
  </reference>
  <reference>
    <citation>Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB, Lopera F, Martins R, Masters CL, Mayeux RP, McDade E, Moreno S, Reiman EM, Ringman JM, Salloway S, Schofield PR, Sperling R, Tariot PN, Xiong C, Morris JC, Bateman RJ; Dominantly Inherited Alzheimer Network. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014 Jul 15;83(3):253-60. doi: 10.1212/WNL.0000000000000596. Epub 2014 Jun 13. Review.</citation>
    <PMID>24928124</PMID>
  </reference>
  <reference>
    <citation>Weng H, Bateman R, Morris JC, Xiong C. Validity and power of minimization algorithm in longitudinal analysis of clinical trials. Biostat Epidemiol. 2017;1(1):59-77. doi: 10.1080/24709360.2017.1331822. Epub 2017 Jun 13.</citation>
    <PMID>29250611</PMID>
  </reference>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>October 14, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <results_first_submitted>February 27, 2021</results_first_submitted>
  <results_first_submitted_qc>August 25, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">September 22, 2022</results_first_posted>
  <disposition_first_submitted>November 19, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>November 19, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 23, 2020</disposition_first_posted>
  <last_update_submitted>August 25, 2022</last_update_submitted>
  <last_update_submitted_qc>August 25, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Dementia</keyword>
  <keyword>Mutation</keyword>
  <keyword>Genetic Mutation</keyword>
  <keyword>Dominantly Inherited Alzheimer's Disease</keyword>
  <keyword>Dominantly Inherited Alzheimer Network</keyword>
  <keyword>Autosomal Dominant Alzheimer's Disease</keyword>
  <keyword>Early Onset Alzheimer's Disease</keyword>
  <keyword>DIAN</keyword>
  <keyword>DIAN-TU</keyword>
  <keyword>DIAN TU</keyword>
  <keyword>DIAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to DIAN-TU trial data will follow the DIAN-TU data access policy, which complies with the guidelines established by the Collaboration for Alzheimer's Prevention [CAP REF].</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT04623242/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT04623242/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study assigned treatment to 194 participants, 1 participant enrolled in the solanezumab arm did not receive treatment. Of the 193 participants, there were 144 mutation positive participants who were treated. Two of these participants did not have post-baseline data and were excluded from the MITT. Forty-nine mutation negative participants were enrolled across the 2 drug arms but are not part of the analysis population.</recruitment_details>
      <pre_assignment_details>Primary analyses used a pooled control group (gantenerumab and solanezumab shared, mutation positive placebo with dynamic borrowing of DIAN-OBS data).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gantenerumab</title>
          <description>Gantenerumab: Subcutaneously every 4 weeks at escalating doses&#xD;
Participants randomized to gantenerumab were then randomized to either active drug or placebo at a 3:1 ratio. All mutation negative participants were assigned to placebo.&#xD;
For analysis purposes, mutation positive placebos were pooled for outcome measures.</description>
        </group>
        <group group_id="P2">
          <title>Solanezumab</title>
          <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses&#xD;
Participants randomized to solanezumab were then randomized to either active drug or placebo at a 3:1 ratio. All mutation negative participants were assigned to placebo.&#xD;
For analysis purposes, mutation positive placebos were pooled for outcome measures. Some secondary measures used direct placebo as specified in the respective outcomes (those randomized to solanezumab only)</description>
        </group>
        <group group_id="P3">
          <title>Mutation Positive Placebo</title>
          <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
        </group>
        <group group_id="P4">
          <title>Mutation Negative Placebo</title>
          <description>Mutation negative participants receiving placebo. Not analyzed as part of the Pooled Placebo Group; analyzed for safety.</description>
        </group>
        <group group_id="P5">
          <title>DIAN-OBS</title>
          <description>Participants from the DIAN Observational study meeting specific criteria as outlined in the posted Statistical Analysis Plan.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="23"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason Not Disclosed to protect treatment and genetic unblinding</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject unblinded to mutation status</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics relative to the primary endpoint measures do not include mutation negative placebos because the primary analysis is only run on the MITT population which excludes mutation negative.</population>
      <group_list>
        <group group_id="B1">
          <title>Gantenerumab</title>
          <description>Gantenerumab: Subcutaneously every 4 weeks at escalating doses</description>
        </group>
        <group group_id="B2">
          <title>Solanezumab</title>
          <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
        </group>
        <group group_id="B3">
          <title>Mutation Positive Placebo</title>
          <description>Mutation Positive Placebos enrolled under each arm but pooled for result reporting.</description>
        </group>
        <group group_id="B4">
          <title>Mutation Negative Placebo</title>
          <description>Mutation Negative Placebos enrolled under each arm but pooled for this reporting.</description>
        </group>
        <group group_id="B5">
          <title>DIAN-OBS Control Group</title>
          <description>Data from participants in the DIAN-OBS study who met DIAN-TU inclusion criteria were used as natural history controls for improved estimates of the placebo group.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="49"/>
            <count group_id="B5" value="69"/>
            <count group_id="B6" value="262"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Represents Age at randomization (DIAN-TU-001) or age at first visit meeting inclusion criteria for DIAN-TU-001 analysis (DIAN-OBS)</description>
          <population>Measure Analysis Population Description: Fifty-two participants were randomized to the solanezumab arm; two did not have post-baseline data and were excluded from the modified intent-to-treat population.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="260"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="10.8"/>
                    <measurement group_id="B2" value="42.7" spread="9.6"/>
                    <measurement group_id="B3" value="44.2" spread="9.6"/>
                    <measurement group_id="B4" value="42.6" spread="9.3"/>
                    <measurement group_id="B5" value="42.3" spread="9.6"/>
                    <measurement group_id="B6" value="43.7" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Measure Analysis Population Description: Fifty-two participants were randomized to the solanezumab arm; two did not have post-baseline data and were excluded from the modified intent-to-treat population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="260"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="47"/>
                    <measurement group_id="B6" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Fifty-two participants were randomized to the solanezumab arm; two did not have post-baseline data and were excluded from the modified intent-to-treat population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="260"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="214"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>Measure Analysis Population Description: Fifty-two participants were randomized to the solanezumab arm; two did not have post-baseline data and were excluded from the modified intent-to-treat population.</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="260"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="260"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="260"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="260"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="260"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="260"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>APOE4</title>
          <description>APOE refers to presence of at least one ε4 allele of apolipoprotein E</description>
          <population>APOE was not included for the external DIAN-OBS Control Group because the data was not available from a CLIA certified lab</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B6" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Enrollment EYO</title>
          <description>EYO represents the estimated years to symptom onset as recorded by the investigator.&#xD;
This EYO is determined based on family history and clinician assessment to determine EYO eligibility for the DIAN-TU-001 trial, and no such assessment was done within DIAN-OBS as there was no EYO requirement for entry.</description>
          <population>Fifty-two participants were randomized to the solanezumab arm; two did not have post-baseline data and were excluded from the modified intent-to-treat population. Data could not be reported for the DIAN-Obs Control group for the International Shopping List Test-Delayed Recall (ISLT) because data was not collected.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-3.5" spread="7.1"/>
                    <measurement group_id="B2" value="-2.4" spread="7.1"/>
                    <measurement group_id="B3" value="-3.5" spread="7.6"/>
                    <measurement group_id="B4" value="-4.8" spread="6.41"/>
                    <measurement group_id="B6" value="-3.25" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Digit Symbol Substitution Test</title>
          <description>Digit Symbol is a subtest of the Wechsler Adult Intelligence Scale (WAIS-R). This test engages multiple cognitive abilities, including attention, psychomotor speed, complex scanning, visual tracking, and immediate memory.&#xD;
Scores range from 0 to 93, with lower scores indicating poorer cognitive performance</description>
          <population>Fifty-two participants were randomized to the solanezumab arm; two did not have post-baseline data and were excluded from the modified intent-to-treat population. DIAN Obs control group only analyzed 68 participants as one participant did not have a baseline measure.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="68"/>
                    <count group_id="B6" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.96" spread="20.56"/>
                    <measurement group_id="B2" value="46.06" spread="19.94"/>
                    <measurement group_id="B3" value="46.63" spread="19.12"/>
                    <measurement group_id="B4" value="60.78" spread="13.01"/>
                    <measurement group_id="B5" value="50.34" spread="18.57"/>
                    <measurement group_id="B6" value="47.76" spread="19.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MMSE</title>
          <description>Mini Mental State Exam is a 30-point test used to measure thinking ability (or &quot;cognitive impairment&quot;).&#xD;
The test measures the following:&#xD;
orientation to time and place (knowing where you are, and the season or day of the week)&#xD;
short-term memory (recall)&#xD;
attention and ability to solve problems (like spelling a simple word backwards)&#xD;
language (identifying common objects by name)&#xD;
comprehension and motor skills (drawing a slightly complicated shape like two pentagons intersecting)&#xD;
Scores range from 0 to 30, with lower scores indicating poorer cognitive performance.</description>
          <population>Fifty-two participants were randomized to the solanezumab arm; two did not have post-baseline data and were excluded from the modified intent-to-treat population. DIAN Obs control group only analyzed 68 participants as one participant did not have a baseline measure.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="68"/>
                    <count group_id="B6" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.10" spread="3.45"/>
                    <measurement group_id="B2" value="26.72" spread="4.11"/>
                    <measurement group_id="B3" value="26.68" spread="3.97"/>
                    <measurement group_id="B4" value="29.08" spread="1.17"/>
                    <measurement group_id="B5" value="26.96" spread="3.22"/>
                    <measurement group_id="B6" value="26.88" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Logical Memory Delayed Recall Test</title>
          <description>Subtest of the Wechsler Memory Scale-Revised Standardized assessment of narrative episodic memory. A short story is orally presented and approximately 20 or 30 min later, examinee is asked to recall the story (delayed recall).&#xD;
Scores range from 0 to 25, with lower scores indicating poorer cognitive performance</description>
          <population>Fifty-two participants were randomized to the solanezumab arm; two did not have post-baseline data and were excluded from the modified intent-to-treat population. Only 51 analyzed for this measure in the gantenerumab as 1 participant did not have a baseline measure.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="51"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.9" spread="6.33"/>
                    <measurement group_id="B2" value="9.86" spread="6.86"/>
                    <measurement group_id="B3" value="9.4" spread="6.45"/>
                    <measurement group_id="B4" value="14.55" spread="3.72"/>
                    <measurement group_id="B5" value="9.32" spread="6.42"/>
                    <measurement group_id="B6" value="9.60" spread="6.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Shopping List Test-Delayed Recall (ISLT)</title>
          <description>International Shopping List Task-Delayed Recall (ISLT) is a classic list-learning test that measures verbal learning &amp; memory.&#xD;
Scores range from 0 to 12, with lower scores indicating poorer cognitive performance.</description>
          <population>Fifty-two participants were randomized to the solanezumab arm; two did not have post-baseline data and were excluded from the modified intent-to-treat population. Only 51 analyzed here for gantenerumab as 1 participant did not have a baseline measure.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="51"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="40"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.96" spread="4.04"/>
                    <measurement group_id="B2" value="6.56" spread="3.95"/>
                    <measurement group_id="B3" value="5.80" spread="4.42"/>
                    <measurement group_id="B4" value="8.80" spread="1.99"/>
                    <measurement group_id="B6" value="6.13" spread="4.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assess Cognitive Efficacy in Individuals With Mutations Causing Dominantly Inherited AD as Measured by the DIAN-Multivariate Cognitive Endpoint (DIAN-MCE);</title>
        <description>Multivariate Disease Progression Model adjusted for Estimated Years to Onset (EYO)and includes all timepoints up to treatment discontinuation. The treatment effect is reported relative to the mutation positive placebo arm.&#xD;
Multivariate Cognitive Endpoint comprising: (i) Wechsler Memory Scale-Revised Logical Memory Delayed Recall Test (MEMUNITS), (ii) Wechsler Adult Intelligence Scale Digit Symbol Substitution Test (WAIS), (iii) Mini-Mental State Examination (MMSE), and (iv) International Shopping List Task (ISLT). Measurements for each test were normalized using the mean (SD) at DIAN-TU-001 baseline for mutation negative subjects. Higher scores indicate more favourable cognitive performance.</description>
        <time_frame>Baseline through Week 260</time_frame>
        <population>The endpoint itself is a ratio based on feeding z-scores for four separate parameters into a model, with programming providing the ratio under model assumptions rather than providing a treatment-specific value this is used to generate the ratio. The four individual parameters are described in other outcomes. There are no &quot;by-arm&quot; values for any MDPM analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Gantenerumab vs. Mutation Positive Placebo</title>
            <description>Gantenerumab: Subcutaneously every 4 weeks at escalating doses; Matching Placebo</description>
          </group>
          <group group_id="O2">
            <title>Solanezumab vs. Mutation Positive Placebo</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses; Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Cognitive Efficacy in Individuals With Mutations Causing Dominantly Inherited AD as Measured by the DIAN-Multivariate Cognitive Endpoint (DIAN-MCE);</title>
          <description>Multivariate Disease Progression Model adjusted for Estimated Years to Onset (EYO)and includes all timepoints up to treatment discontinuation. The treatment effect is reported relative to the mutation positive placebo arm.&#xD;
Multivariate Cognitive Endpoint comprising: (i) Wechsler Memory Scale-Revised Logical Memory Delayed Recall Test (MEMUNITS), (ii) Wechsler Adult Intelligence Scale Digit Symbol Substitution Test (WAIS), (iii) Mini-Mental State Examination (MMSE), and (iv) International Shopping List Task (ISLT). Measurements for each test were normalized using the mean (SD) at DIAN-TU-001 baseline for mutation negative subjects. Higher scores indicate more favourable cognitive performance.</description>
          <population>The endpoint itself is a ratio based on feeding z-scores for four separate parameters into a model, with programming providing the ratio under model assumptions rather than providing a treatment-specific value this is used to generate the ratio. The four individual parameters are described in other outcomes. There are no &quot;by-arm&quot; values for any MDPM analysis.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.063" spread="0.059"/>
                    <measurement group_id="O2" value="1.255" spread="0.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>1.063</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.059</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>1.255</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.061</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gantenerumab: Rate of Change Over Time- Clinical Dementia Rating Sum of Boxes (CDR-SB)</title>
        <description>CDR-SB score is considered a more detailed quantitative general index of cognition and function, and provides more information than the global CDR score in patients with mild dementia&#xD;
Scores range from 0-18 with lower scores showing more favorable cognitive function.</description>
        <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Gantenerumab</title>
            <description>Gantenerumab: Subcutaneously every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Gantenerumab: Rate of Change Over Time- Clinical Dementia Rating Sum of Boxes (CDR-SB)</title>
          <description>CDR-SB score is considered a more detailed quantitative general index of cognition and function, and provides more information than the global CDR score in patients with mild dementia&#xD;
Scores range from 0-18 with lower scores showing more favorable cognitive function.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.202"/>
                    <measurement group_id="O2" value="0.44" spread="0.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="0.364"/>
                    <measurement group_id="O2" value="1.36" spread="0.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.511"/>
                    <measurement group_id="O2" value="2.28" spread="0.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" spread="0.726"/>
                    <measurement group_id="O2" value="3.24" spread="0.819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.61" spread="1.220"/>
                    <measurement group_id="O2" value="5.76" spread="1.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.805</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.094</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.46</ci_lower_limit>
            <ci_upper_limit>1.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gantenerumab: Rate of Change Over Time- Functional Assessment Scale (FAS)</title>
        <description>The Functional Assessment Scale is to be administered and completed by the study partner about subjects for whom they care. This scale measures instrumental activities of daily living such as preparing balanced meals and managing personal finances. The intent of the FAS is to assess change in an individual's functional activities, relative to previously attained abilities, that are caused by cognitive dysfunction. If the study partner indicates that the subject no longer performs a particular task, it is reasonable to probe further and ask if they think the subject could still do the task. This will help tease out the relevant cognitive impairment</description>
        <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Gantenerumab</title>
            <description>Gantenerumab: Subcutaneously every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Gantenerumab: Rate of Change Over Time- Functional Assessment Scale (FAS)</title>
          <description>The Functional Assessment Scale is to be administered and completed by the study partner about subjects for whom they care. This scale measures instrumental activities of daily living such as preparing balanced meals and managing personal finances. The intent of the FAS is to assess change in an individual's functional activities, relative to previously attained abilities, that are caused by cognitive dysfunction. If the study partner indicates that the subject no longer performs a particular task, it is reasonable to probe further and ask if they think the subject could still do the task. This will help tease out the relevant cognitive impairment</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="0.408"/>
                    <measurement group_id="O2" value="1.40" spread="0.469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34" spread="0.680"/>
                    <measurement group_id="O2" value="2.44" spread="0.790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" spread="0.921"/>
                    <measurement group_id="O2" value="4.07" spread="1.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.34" spread="1.202"/>
                    <measurement group_id="O2" value="5.55" spread="1.373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.40" spread="1.730"/>
                    <measurement group_id="O2" value="5.69" spread="2.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of equality (any treatment difference)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.512</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.823</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.83</ci_lower_limit>
            <ci_upper_limit>2.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gantenerumab: Imaging Measures Composite [11C] PiB Partial Volume Corrected Regional Spread Function Standardized Uptake Value Ratio - Composite</title>
        <description>In vivo quantification of β-amyloid deposition using positron emission tomography. This measure is a composite of brain regions. Higher scores indicate worse disease stage.</description>
        <time_frame>Baseline, Weeks 52, 104 and 208</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Gantenerumab</title>
            <description>Gantenerumab: Subcutaneously every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Gantenerumab: Imaging Measures Composite [11C] PiB Partial Volume Corrected Regional Spread Function Standardized Uptake Value Ratio - Composite</title>
          <description>In vivo quantification of β-amyloid deposition using positron emission tomography. This measure is a composite of brain regions. Higher scores indicate worse disease stage.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" spread="0.0402"/>
                    <measurement group_id="O2" value="0.103" spread="0.0454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.106" spread="0.0422"/>
                    <measurement group_id="O2" value="0.134" spread="0.0470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.334" spread="0.0736"/>
                    <measurement group_id="O2" value="0.306" spread="0.0839"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.641</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1115</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.864</ci_lower_limit>
            <ci_upper_limit>-0.417</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Clinical Measures- Clinical Dementia Rating (CDR)</title>
        <description>Clinical Dementia Rating - Global Score - Number of Subjects with an Increase from Baseline by Visit</description>
        <time_frame>Baseline and Weeks 52, 104, 156, and 208</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Clinical Measures- Clinical Dementia Rating (CDR)</title>
          <description>Clinical Dementia Rating - Global Score - Number of Subjects with an Increase from Baseline by Visit</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase from baseline CDR Global Score</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No increase from baseline CDR Global Score</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase from baseline CDR Global Score</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No increase from baseline CDR Global Score</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase from baseline CDR Global Score</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No increase from baseline CDR Global Score</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase from baseline CDR Global Score</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No increase from baseline CDR Global Score</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase from baseline CDR Global Score</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No increase from baseline CDR Global Score</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any difference in the proportion of increase in the endpoint)</non_inferiority_desc>
            <p_value>0.5573</p_value>
            <method>Chi-squared</method>
            <param_type>Ratio</param_type>
            <param_value>0.3443</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Clinical Measures- CDR Sum of Boxes (CDR-SB)</title>
        <description>CDR-SB score is considered a more detailed quantitative general index and provides more information than the global CDR score in patients with mild dementia&#xD;
Scores range from 0-18 with lower scores showing more favorable cognitive function.</description>
        <time_frame>Baseline and Weeks 52, 104, 156, and 208</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Clinical Measures- CDR Sum of Boxes (CDR-SB)</title>
          <description>CDR-SB score is considered a more detailed quantitative general index and provides more information than the global CDR score in patients with mild dementia&#xD;
Scores range from 0-18 with lower scores showing more favorable cognitive function.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.208"/>
                    <measurement group_id="O2" value="0.44" spread="0.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.367"/>
                    <measurement group_id="O2" value="1.36" spread="0.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" spread="0.512"/>
                    <measurement group_id="O2" value="2.28" spread="0.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.65" spread="0.723"/>
                    <measurement group_id="O2" value="3.24" spread="0.819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" spread="1.212"/>
                    <measurement group_id="O2" value="5.76" spread="1.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.707</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.092</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.77</ci_lower_limit>
            <ci_upper_limit>2.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Clinical Measures- Geriatric Depression Scale (GDS)</title>
        <description>The Geriatric Depression Scale (GDS) is a self-report measure of depression in older adults. Users respond in a &quot;Yes/No&quot; format. Of the 15 items, 10 indicate the presence of depression when answered positively while the other 5 are indicative of depression when answered negatively.&#xD;
Scores range from 0-15 for completed questionnaires. A score of 88 is recorded for participants unable to complete the test.&#xD;
Lower scores show more favorable outcome.</description>
        <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Clinical Measures- Geriatric Depression Scale (GDS)</title>
          <description>The Geriatric Depression Scale (GDS) is a self-report measure of depression in older adults. Users respond in a &quot;Yes/No&quot; format. Of the 15 items, 10 indicate the presence of depression when answered positively while the other 5 are indicative of depression when answered negatively.&#xD;
Scores range from 0-15 for completed questionnaires. A score of 88 is recorded for participants unable to complete the test.&#xD;
Lower scores show more favorable outcome.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.230"/>
                    <measurement group_id="O2" value="-0.14" spread="0.255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.265"/>
                    <measurement group_id="O2" value="0.03" spread="0.304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.250"/>
                    <measurement group_id="O2" value="-0.07" spread="0.276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.294"/>
                    <measurement group_id="O2" value="0.36" spread="0.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.544"/>
                    <measurement group_id="O2" value="0.66" spread="0.820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.283</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.440</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.35</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Clinical Measures- Neuropsychiatric Inventory Questionnaire (NPI-Q)</title>
        <description>The questionnaire is to be administered and completed by the study partner about patients for whom they care. Each of the 12 NPI-Q domains contains a survey question that reflects cardinal symptoms of that domain. Initial responses to each domain question are &quot;Yes&quot;(present) or &quot;No&quot; (absent). If the response to the domain question is &quot;No&quot;, the study partner goes to the next question. If &quot;Yes&quot;, the study partner then rates both the Severity of the symptoms present within the last month on a 3-point scale and the associated impact of the symptom manifestations on them (i.e. Caregiver Distress) using a 5-point scale. The NPI-Q provides symptom 'Severity' and 'Distress' ratings for each symptom reported, and total 'Severity' and 'Distress' scores reflecting the sum of individual domain scores.&#xD;
Scores range from 0-36 with lower scores indicating more favorable cognitive function.</description>
        <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Clinical Measures- Neuropsychiatric Inventory Questionnaire (NPI-Q)</title>
          <description>The questionnaire is to be administered and completed by the study partner about patients for whom they care. Each of the 12 NPI-Q domains contains a survey question that reflects cardinal symptoms of that domain. Initial responses to each domain question are &quot;Yes&quot;(present) or &quot;No&quot; (absent). If the response to the domain question is &quot;No&quot;, the study partner goes to the next question. If &quot;Yes&quot;, the study partner then rates both the Severity of the symptoms present within the last month on a 3-point scale and the associated impact of the symptom manifestations on them (i.e. Caregiver Distress) using a 5-point scale. The NPI-Q provides symptom 'Severity' and 'Distress' ratings for each symptom reported, and total 'Severity' and 'Distress' scores reflecting the sum of individual domain scores.&#xD;
Scores range from 0-36 with lower scores indicating more favorable cognitive function.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.416"/>
                    <measurement group_id="O2" value="1.06" spread="0.460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="0.463"/>
                    <measurement group_id="O2" value="1.54" spread="0.530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.459"/>
                    <measurement group_id="O2" value="1.10" spread="0.522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.575"/>
                    <measurement group_id="O2" value="1.74" spread="0.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.934"/>
                    <measurement group_id="O2" value="1.16" spread="1.212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.674</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.859</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.34</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Clinical Measures- Functional Assessment Scale (FAS)</title>
        <description>The Functional Assessment Scale is to be administered and completed by the study partner about subjects for whom they care. This scale measures instrumental activities of daily living such as preparing balanced meals and managing personal finances. The intent of the FAS is to assess change in an individual's functional activities, relative to previously attained abilities, that are caused by cognitive dysfunction. If the study partner indicates that the subject no longer performs a particular task, it is reasonable to probe further and ask if they think the subject could still do the task. This will help tease out the relevant cognitive impairment&#xD;
Scores range from 0-30 with lower scores indicate more favorable cognitive performance</description>
        <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Clinical Measures- Functional Assessment Scale (FAS)</title>
          <description>The Functional Assessment Scale is to be administered and completed by the study partner about subjects for whom they care. This scale measures instrumental activities of daily living such as preparing balanced meals and managing personal finances. The intent of the FAS is to assess change in an individual's functional activities, relative to previously attained abilities, that are caused by cognitive dysfunction. If the study partner indicates that the subject no longer performs a particular task, it is reasonable to probe further and ask if they think the subject could still do the task. This will help tease out the relevant cognitive impairment&#xD;
Scores range from 0-30 with lower scores indicate more favorable cognitive performance</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.430"/>
                    <measurement group_id="O2" value="1.40" spread="0.469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="0.690"/>
                    <measurement group_id="O2" value="2.44" spread="0.790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" spread="0.926"/>
                    <measurement group_id="O2" value="4.07" spread="1.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="1.208"/>
                    <measurement group_id="O2" value="5.55" spread="1.373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.82" spread="1.748"/>
                    <measurement group_id="O2" value="5.69" spread="2.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.507</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.828</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.86</ci_lower_limit>
            <ci_upper_limit>2.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Clinical Measures- Mini-Mental Status State Examination (MMSE)</title>
        <description>MMSE is a brief, quantitative measure of cognitive status in adults used to screen for cognitive impairment, to estimate the severity of cognitive impairment at a given point in time, to follow the course of cognitive changes in an individual over time, and to document an individual's response to treatment.&#xD;
Scores range from 0-30 and higher scores indicate more favorable cognitive function.</description>
        <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Clinical Measures- Mini-Mental Status State Examination (MMSE)</title>
          <description>MMSE is a brief, quantitative measure of cognitive status in adults used to screen for cognitive impairment, to estimate the severity of cognitive impairment at a given point in time, to follow the course of cognitive changes in an individual over time, and to document an individual's response to treatment.&#xD;
Scores range from 0-30 and higher scores indicate more favorable cognitive function.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="0.354"/>
                    <measurement group_id="O2" value="-0.83" spread="0.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.59" spread="0.603"/>
                    <measurement group_id="O2" value="-1.73" spread="0.677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.76" spread="0.858"/>
                    <measurement group_id="O2" value="-3.23" spread="0.964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.31" spread="1.137"/>
                    <measurement group_id="O2" value="-4.30" spread="1.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.88" spread="1.799"/>
                    <measurement group_id="O2" value="-5.94" spread="2.143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.553</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.706</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.41</ci_lower_limit>
            <ci_upper_limit>2.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Cognitive Measures- International Shopping List Task 30-Minute Delayed Recall</title>
        <description>Classic list-learning test that measures verbal learning &amp; memory.&#xD;
Scores range from 0-12 with higher scores indicating more favorable cognitive performance.</description>
        <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Cognitive Measures- International Shopping List Task 30-Minute Delayed Recall</title>
          <description>Classic list-learning test that measures verbal learning &amp; memory.&#xD;
Scores range from 0-12 with higher scores indicating more favorable cognitive performance.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.248"/>
                    <measurement group_id="O2" value="-0.17" spread="0.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.98" spread="0.300"/>
                    <measurement group_id="O2" value="-0.64" spread="0.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" spread="0.294"/>
                    <measurement group_id="O2" value="-0.42" spread="0.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="0.396"/>
                    <measurement group_id="O2" value="-0.93" spread="0.447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" spread="0.548"/>
                    <measurement group_id="O2" value="-1.86" spread="0.680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.098</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.596</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.18</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Cognitive Measures- Groton Maze Learning Test 30 Minute Delayed Recall</title>
        <description>The Groton Maze Learning Test 30 minute delayed recall measures episodic memory. The primary outcome is the number of errors made during recall of the previously memorized pathway from the Groton Maze Learning Test. The minimum score is 0 errors and the max is 999. Lower scores indicate better cognitive performance.</description>
        <time_frame>Baseline, Week 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end). Tasks are only included where assessed for subjects with a baseline Clinical Dementia Rating Global Score less than 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Cognitive Measures- Groton Maze Learning Test 30 Minute Delayed Recall</title>
          <description>The Groton Maze Learning Test 30 minute delayed recall measures episodic memory. The primary outcome is the number of errors made during recall of the previously memorized pathway from the Groton Maze Learning Test. The minimum score is 0 errors and the max is 999. Lower scores indicate better cognitive performance.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end). Tasks are only included where assessed for subjects with a baseline Clinical Dementia Rating Global Score less than 1.</population>
          <units>count of errors</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.975"/>
                    <measurement group_id="O2" value="-0.13" spread="1.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="1.108"/>
                    <measurement group_id="O2" value="0.78" spread="1.207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="1.055"/>
                    <measurement group_id="O2" value="0.96" spread="1.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="1.319"/>
                    <measurement group_id="O2" value="1.60" spread="1.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.11" spread="2.894"/>
                    <measurement group_id="O2" value="6.99" spread="3.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.173</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.980</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.22</ci_lower_limit>
            <ci_upper_limit>6.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Cognitive Measures- Groton Maze Learning Test Delayed Reversed Recall</title>
        <description>The Groton Maze Learning Test measures executive function using a maze learning paradigm. A 10 x 10 grid of tiles is presented to the participant on the screen. A 28-step pathway is hidden among these tiles. A blue tile indicates the start and a tile with red circles indicates the finish. The participant must move one step at a time from the start toward the end by touching a tile next to their current location. If the correct move is made a green checkmark appears and if the move is incorrect a red cross is revealed. Once completed, they are returned to the start location to repeat the test and must try to remember the pathway they have just completed. &quot;Delayed Reverse Recall&quot; measures spatial working memory.&#xD;
The outcome is the number of errors made with the range of 0-999. Lower scores indicate better cognitive performance.</description>
        <time_frame>Baseline, Week 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end). Tasks are only included where assessed for subjects with a baseline Clinical Dementia Rating Global Score less than 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Cognitive Measures- Groton Maze Learning Test Delayed Reversed Recall</title>
          <description>The Groton Maze Learning Test measures executive function using a maze learning paradigm. A 10 x 10 grid of tiles is presented to the participant on the screen. A 28-step pathway is hidden among these tiles. A blue tile indicates the start and a tile with red circles indicates the finish. The participant must move one step at a time from the start toward the end by touching a tile next to their current location. If the correct move is made a green checkmark appears and if the move is incorrect a red cross is revealed. Once completed, they are returned to the start location to repeat the test and must try to remember the pathway they have just completed. &quot;Delayed Reverse Recall&quot; measures spatial working memory.&#xD;
The outcome is the number of errors made with the range of 0-999. Lower scores indicate better cognitive performance.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end). Tasks are only included where assessed for subjects with a baseline Clinical Dementia Rating Global Score less than 1.</population>
          <units>number of errors</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.08" spread="2.686"/>
                    <measurement group_id="O2" value="-1.34" spread="2.858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.21" spread="2.715"/>
                    <measurement group_id="O2" value="3.28" spread="2.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45" spread="2.490"/>
                    <measurement group_id="O2" value="1.82" spread="2.711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.59" spread="2.658"/>
                    <measurement group_id="O2" value="5.29" spread="2.980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.25" spread="10.722"/>
                    <measurement group_id="O2" value="6.75" spread="15.509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.940</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.998</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.10</ci_lower_limit>
            <ci_upper_limit>8.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Cognitive Measures- Trailmaking Test Part A</title>
        <description>Trail Making test taps attention, processing speed, and executive function. Part A consists of 25 circles numbered 1 through 25 distributed over a white sheet of standard document-sized paper. The subject is instructed to connect the circles with a drawn line as quickly as possible in ascending numerical order without lifting their pen.&#xD;
The subject's performance is judged in terms of the time, in seconds, required to complete each trail (Max time 150 seconds). Lower scores indicate more favorable cognitive function.</description>
        <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Cognitive Measures- Trailmaking Test Part A</title>
          <description>Trail Making test taps attention, processing speed, and executive function. Part A consists of 25 circles numbered 1 through 25 distributed over a white sheet of standard document-sized paper. The subject is instructed to connect the circles with a drawn line as quickly as possible in ascending numerical order without lifting their pen.&#xD;
The subject's performance is judged in terms of the time, in seconds, required to complete each trail (Max time 150 seconds). Lower scores indicate more favorable cognitive function.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.73" spread="2.895"/>
                    <measurement group_id="O2" value="5.14" spread="3.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.03" spread="4.473"/>
                    <measurement group_id="O2" value="11.38" spread="5.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.45" spread="5.832"/>
                    <measurement group_id="O2" value="15.21" spread="6.538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.69" spread="11.028"/>
                    <measurement group_id="O2" value="32.63" spread="12.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.49" spread="27.664"/>
                    <measurement group_id="O2" value="89.02" spread="32.699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.854</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>16.524</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.49</ci_lower_limit>
            <ci_upper_limit>36.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Cognitive Measures- Trailmaking Test Part B</title>
        <description>This test taps attention, processing speed, and executive function and depends on visuo-motor and perceptual-scanning skills and also requires considerable cognitive flexibility in shifting from number to letter sets under time pressure. Part B consists of 25 circles, but these circles contain either numbers (1 through 13) or letters (A through L). The subject must connect the circles while alternating between numbers and letters in an ascending order (e.g., A to 1; 1 to B; B to 2; 2 to C).&#xD;
The subject's performance is judged in terms of the time, in seconds, required to complete each Trail (Max of 300 seconds). Lower scores indicate more favorable cognitive function.</description>
        <time_frame>Baseline, Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Cognitive Measures- Trailmaking Test Part B</title>
          <description>This test taps attention, processing speed, and executive function and depends on visuo-motor and perceptual-scanning skills and also requires considerable cognitive flexibility in shifting from number to letter sets under time pressure. Part B consists of 25 circles, but these circles contain either numbers (1 through 13) or letters (A through L). The subject must connect the circles while alternating between numbers and letters in an ascending order (e.g., A to 1; 1 to B; B to 2; 2 to C).&#xD;
The subject's performance is judged in terms of the time, in seconds, required to complete each Trail (Max of 300 seconds). Lower scores indicate more favorable cognitive function.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>number of seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.39" spread="6.582"/>
                    <measurement group_id="O2" value="8.00" spread="7.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="7.626"/>
                    <measurement group_id="O2" value="10.52" spread="8.710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.59" spread="11.619"/>
                    <measurement group_id="O2" value="21.35" spread="13.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.42" spread="11.539"/>
                    <measurement group_id="O2" value="16.54" spread="13.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.44" spread="25.139"/>
                    <measurement group_id="O2" value="37.62" spread="33.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.781</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>17.448</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.00</ci_lower_limit>
            <ci_upper_limit>39.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Cognitive Measures- WAIS-R Digit-Symbol Substitution Test</title>
        <description>This test engages multiple cognitive abilities, including attention, psychomotor speed, complex scanning, visual tracking, and immediate memory.&#xD;
Scores range from 0-93 with higher scores indicate more favorable cognitive function.</description>
        <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Cognitive Measures- WAIS-R Digit-Symbol Substitution Test</title>
          <description>This test engages multiple cognitive abilities, including attention, psychomotor speed, complex scanning, visual tracking, and immediate memory.&#xD;
Scores range from 0-93 with higher scores indicate more favorable cognitive function.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="1.149"/>
                    <measurement group_id="O2" value="-1.02" spread="1.283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" spread="1.744"/>
                    <measurement group_id="O2" value="0.20" spread="1.965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.64" spread="2.232"/>
                    <measurement group_id="O2" value="-1.72" spread="2.540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.83" spread="2.784"/>
                    <measurement group_id="O2" value="-6.15" spread="3.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.96" spread="4.057"/>
                    <measurement group_id="O2" value="-9.60" spread="4.898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.689</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.210</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.05</ci_lower_limit>
            <ci_upper_limit>6.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Cognitive Measures- WMS-R Digit Span Backward</title>
        <description>Widely used measure of working memory (or attention) in which the subject is read number sequences of increasing length and then asked to repeat each sequence backward. The primary measure of performance is the number of digit sequences correctly reversed.&#xD;
The unit of measure is number of digit sequences correctly recalled and ranges from 0-12. Higher scores indicate more favorable cognitive function.</description>
        <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Cognitive Measures- WMS-R Digit Span Backward</title>
          <description>Widely used measure of working memory (or attention) in which the subject is read number sequences of increasing length and then asked to repeat each sequence backward. The primary measure of performance is the number of digit sequences correctly reversed.&#xD;
The unit of measure is number of digit sequences correctly recalled and ranges from 0-12. Higher scores indicate more favorable cognitive function.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>number of correct sequences recalled</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.241"/>
                    <measurement group_id="O2" value="-0.12" spread="0.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.272"/>
                    <measurement group_id="O2" value="-0.16" spread="0.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" spread="0.370"/>
                    <measurement group_id="O2" value="-0.28" spread="0.415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="0.460"/>
                    <measurement group_id="O2" value="-0.68" spread="0.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="0.657"/>
                    <measurement group_id="O2" value="-1.22" spread="0.832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.474</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.689</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.86</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Cognitive Measures- WMS-R Digit Span Forward</title>
        <description>This is a widely-used test of working memory in which the subject is read number sequences of increasing length and asked to repeat them. The total score is the number of sequences correctly repeated.&#xD;
The unit of measure is number of digit sequences correctly recalled and ranges from 0-12. Higher scores indicate more favorable cognitive function.</description>
        <time_frame>Baseline, Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Cognitive Measures- WMS-R Digit Span Forward</title>
          <description>This is a widely-used test of working memory in which the subject is read number sequences of increasing length and asked to repeat them. The total score is the number of sequences correctly repeated.&#xD;
The unit of measure is number of digit sequences correctly recalled and ranges from 0-12. Higher scores indicate more favorable cognitive function.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>number of correct sequences recalled</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="0.220"/>
                    <measurement group_id="O2" value="-0.38" spread="0.242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" spread="0.290"/>
                    <measurement group_id="O2" value="-0.84" spread="0.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.50" spread="0.346"/>
                    <measurement group_id="O2" value="-1.23" spread="0.387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.96" spread="0.424"/>
                    <measurement group_id="O2" value="-1.86" spread="0.475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.05" spread="0.722"/>
                    <measurement group_id="O2" value="-1.06" spread="0.929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.886</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.637</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.36</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Cognitive Measures- Raven's Progressive Matrices (Set A)</title>
        <description>This is a measure of fluid intelligence. This test is used to get an estimate of the subjects IQ at baseline. Subjects are asked to complete a visual pattern by circling one of six response choices.&#xD;
Scores range from 0-12 with higher scores indicating more favorable cognitive performance.</description>
        <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Cognitive Measures- Raven's Progressive Matrices (Set A)</title>
          <description>This is a measure of fluid intelligence. This test is used to get an estimate of the subjects IQ at baseline. Subjects are asked to complete a visual pattern by circling one of six response choices.&#xD;
Scores range from 0-12 with higher scores indicating more favorable cognitive performance.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.235"/>
                    <measurement group_id="O2" value="-0.70" spread="0.261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.93" spread="0.310"/>
                    <measurement group_id="O2" value="-0.63" spread="0.350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="0.366"/>
                    <measurement group_id="O2" value="-1.06" spread="0.408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" spread="0.372"/>
                    <measurement group_id="O2" value="-1.53" spread="0.416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.11" spread="0.873"/>
                    <measurement group_id="O2" value="-1.78" spread="1.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.873</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.556</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Cognitive Measures- Category Fluency (Animals)</title>
        <description>Category Fluency is a widely used measure of semantic memory (verbal fluency, language). The subject is asked to name different exemplars of a given semantic category (animals), and the number of unique exemplars named is scored.&#xD;
Higher scores indicate more favorable cognitive function.</description>
        <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Cognitive Measures- Category Fluency (Animals)</title>
          <description>Category Fluency is a widely used measure of semantic memory (verbal fluency, language). The subject is asked to name different exemplars of a given semantic category (animals), and the number of unique exemplars named is scored.&#xD;
Higher scores indicate more favorable cognitive function.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" spread="0.642"/>
                    <measurement group_id="O2" value="-2.19" spread="0.711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.64" spread="0.754"/>
                    <measurement group_id="O2" value="-2.50" spread="0.860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.84" spread="0.869"/>
                    <measurement group_id="O2" value="-2.46" spread="0.974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.69" spread="1.105"/>
                    <measurement group_id="O2" value="-3.27" spread="1.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.45" spread="1.761"/>
                    <measurement group_id="O2" value="-6.50" spread="2.303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.394</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.660</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.71</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Cognitive Measures- Category Fluency (Vegetables)</title>
        <description>Category Fluency is a widely used measure of semantic memory (verbal fluency, language). The subject is asked to name different exemplars of a given semantic category (vegetables), and the number of unique exemplars named is scored.&#xD;
Higher scores indicate more favorable cognitive function.</description>
        <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Cognitive Measures- Category Fluency (Vegetables)</title>
          <description>Category Fluency is a widely used measure of semantic memory (verbal fluency, language). The subject is asked to name different exemplars of a given semantic category (vegetables), and the number of unique exemplars named is scored.&#xD;
Higher scores indicate more favorable cognitive function.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.481"/>
                    <measurement group_id="O2" value="-1.41" spread="0.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="0.539"/>
                    <measurement group_id="O2" value="-1.74" spread="0.619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="0.555"/>
                    <measurement group_id="O2" value="-1.43" spread="0.623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.03" spread="0.707"/>
                    <measurement group_id="O2" value="-1.72" spread="0.794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.36" spread="1.069"/>
                    <measurement group_id="O2" value="-2.23" spread="1.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.776</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.063</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.41</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Cognitive Measures- WMS-R Logical Memory Delayed Recall Test</title>
        <description>Measure of delayed recall (episodic memory) of a story read to the subject at the beginning of the testing session and subject is asked to relay the story 20 minutes later.&#xD;
Scores range from 0-25 with higher scores indicating more favorable cognitive performance.</description>
        <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Pooled Placebo</title>
            <description>Placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Cognitive Measures- WMS-R Logical Memory Delayed Recall Test</title>
          <description>Measure of delayed recall (episodic memory) of a story read to the subject at the beginning of the testing session and subject is asked to relay the story 20 minutes later.&#xD;
Scores range from 0-25 with higher scores indicating more favorable cognitive performance.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.397"/>
                    <measurement group_id="O2" value="1.33" spread="0.441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.501"/>
                    <measurement group_id="O2" value="1.71" spread="0.576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="0.549"/>
                    <measurement group_id="O2" value="2.37" spread="0.618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.606"/>
                    <measurement group_id="O2" value="1.82" spread="0.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="1.029"/>
                    <measurement group_id="O2" value="2.68" spread="1.416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.283</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.909</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.78</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Cognitive Measures- WMS-R Logical Memory Immediate Recall Test</title>
        <description>This test assesses the ability to recall a short story. The subject is read a short story and immediately after hearing the story, the subject is asked to retell the story from memory.&#xD;
Scores range from 0-25 with higher scores indicating more favorable cognitive performance.</description>
        <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Cognitive Measures- WMS-R Logical Memory Immediate Recall Test</title>
          <description>This test assesses the ability to recall a short story. The subject is read a short story and immediately after hearing the story, the subject is asked to retell the story from memory.&#xD;
Scores range from 0-25 with higher scores indicating more favorable cognitive performance.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.452"/>
                    <measurement group_id="O2" value="-0.06" spread="0.501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.510"/>
                    <measurement group_id="O2" value="0.75" spread="0.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.573"/>
                    <measurement group_id="O2" value="0.91" spread="0.646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.631"/>
                    <measurement group_id="O2" value="0.69" spread="0.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="1.018"/>
                    <measurement group_id="O2" value="1.37" spread="1.420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.634</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.947</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.33</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Cognitive Measures- Composite Including: Alternative Multivariate Composite: (1) Digit Span Backwards; (2) Logical Memory (Immediate); (3) Trailmaking B; (4) Category Fluency (Animals)</title>
        <description>Multivariate Disease Progression Model adjusted for estimated years from symptom onset (EYO) and includes all time points up to treatment discontinuation. The treatment effect for Solanezumab is reported relative to the mutation positive placebo arm.&#xD;
This alternative multivariate endpoint includes four tests: Logical Memory Immediate Recall, Digit Span Backward Recall, Category Fluency (Animals), Trailmaking Test Part B. Measurements for each test will be normalized using the mean (SD) at DIAN-TU-001 baseline among mutation negative subjects before being analyzed. For the Trailmaking Test B, the scores will be multiplied by -1 as higher scores indicate worse performance; whereas for the other three, lower scores indicate worse performance. Therefore, on the standardized endpoints, lower scores indicate worse performance.</description>
        <time_frame>Baseline through Week 260</time_frame>
        <population>The endpoint itself is a ratio based on feeding z-scores for four separate parameters into a model, with programming providing the ratio under model assumptions rather than providing a treatment-specific value this is used to generate the ratio. The four individual parameters are described in other outcomes. There are no &quot;by-arm&quot; values for any MDPM analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab vs. Mutation Positive Placebo Plus DIAN-OBS Control Group</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses; Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Cognitive Measures- Composite Including: Alternative Multivariate Composite: (1) Digit Span Backwards; (2) Logical Memory (Immediate); (3) Trailmaking B; (4) Category Fluency (Animals)</title>
          <description>Multivariate Disease Progression Model adjusted for estimated years from symptom onset (EYO) and includes all time points up to treatment discontinuation. The treatment effect for Solanezumab is reported relative to the mutation positive placebo arm.&#xD;
This alternative multivariate endpoint includes four tests: Logical Memory Immediate Recall, Digit Span Backward Recall, Category Fluency (Animals), Trailmaking Test Part B. Measurements for each test will be normalized using the mean (SD) at DIAN-TU-001 baseline among mutation negative subjects before being analyzed. For the Trailmaking Test B, the scores will be multiplied by -1 as higher scores indicate worse performance; whereas for the other three, lower scores indicate worse performance. Therefore, on the standardized endpoints, lower scores indicate worse performance.</description>
          <population>The endpoint itself is a ratio based on feeding z-scores for four separate parameters into a model, with programming providing the ratio under model assumptions rather than providing a treatment-specific value this is used to generate the ratio. The four individual parameters are described in other outcomes. There are no &quot;by-arm&quot; values for any MDPM analysis.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.155" spread="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>1.155</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.074</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Imaging Measures- Brain Amyloid Load as Measured by [11C]PiB-PET Non-partial Volume Corrected</title>
        <description>PiB Standardized Uptake Value Ratio ([11C]PiB SUVR) is the most common quantitative method used to make regional comparisons within a subject as well as between subjects and computed as the degree of radiotracer uptake in a target region of interest (regions dervived via automated segmentation using FreeSurfer) with respect to a reference region. In amyloid and tau imaging, SUVR is typically generated using some portion or the entire cerebellum as a reference because cerebellum is not affected until late in the progression of AD.</description>
        <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Imaging Measures- Brain Amyloid Load as Measured by [11C]PiB-PET Non-partial Volume Corrected</title>
          <description>PiB Standardized Uptake Value Ratio ([11C]PiB SUVR) is the most common quantitative method used to make regional comparisons within a subject as well as between subjects and computed as the degree of radiotracer uptake in a target region of interest (regions dervived via automated segmentation using FreeSurfer) with respect to a reference region. In amyloid and tau imaging, SUVR is typically generated using some portion or the entire cerebellum as a reference because cerebellum is not affected until late in the progression of AD.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.030" spread="0.0147"/>
                    <measurement group_id="O2" value="0.025" spread="0.0164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.019" spread="0.0180"/>
                    <measurement group_id="O2" value="0.022" spread="0.0200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.113" spread="0.0387"/>
                    <measurement group_id="O2" value="0.093" spread="0.0408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.726</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.020</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0562</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.093</ci_lower_limit>
            <ci_upper_limit>0.132</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Imaging Measures- Brain Amyloid Load as Measured by Florbetapir PET</title>
        <description>Florbetapir Standardized Uptake Value Ratio ([18F]AV-45 SUVR) is the most common quantitative method used to make regional comparisons within a subject as well as between subjects and computed as the degree of radiotracer uptake in a target region of interest (regions derivved via automated segmentation using FreeSurfer) with respect to a reference region. In amyloid and tau imaging, SUVR is typically generated using some portion or the entire cerebellum as a reference because cerebellum is not affected until late in the progression of AD.</description>
        <time_frame>Weeks104 and 208</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was notcollected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Imaging Measures- Brain Amyloid Load as Measured by Florbetapir PET</title>
          <description>Florbetapir Standardized Uptake Value Ratio ([18F]AV-45 SUVR) is the most common quantitative method used to make regional comparisons within a subject as well as between subjects and computed as the degree of radiotracer uptake in a target region of interest (regions derivved via automated segmentation using FreeSurfer) with respect to a reference region. In amyloid and tau imaging, SUVR is typically generated using some portion or the entire cerebellum as a reference because cerebellum is not affected until late in the progression of AD.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was notcollected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.066" spread="0.0458"/>
                    <measurement group_id="O2" value="0.105" spread="0.0511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.251" spread="0.0717"/>
                    <measurement group_id="O2" value="0.168" spread="0.0775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.439</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.082</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.130</ci_lower_limit>
            <ci_upper_limit>0.295</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Imaging Measures- Brain Glucose Metabolism as Measured by Fluorodeoxyglucose (FDG)-PET Non-partial Volume Corrected</title>
        <description>FDG Standardized Uptake Value Ratio ([18F]FDG SUVR) is the most common quantitative method used to make regional comparisons within a subject as well as between subjects and computed as the degree of radiotracer uptake in a target region of interest (regions derivved via automated segmentation using FreeSurfer) with respect to a reference region. In amyloid and tau imaging, SUVR is typically generated using some portion or the entire cerebellum as a reference because cerebellum is not affected until late in the progression of AD.</description>
        <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Imaging Measures- Brain Glucose Metabolism as Measured by Fluorodeoxyglucose (FDG)-PET Non-partial Volume Corrected</title>
          <description>FDG Standardized Uptake Value Ratio ([18F]FDG SUVR) is the most common quantitative method used to make regional comparisons within a subject as well as between subjects and computed as the degree of radiotracer uptake in a target region of interest (regions derivved via automated segmentation using FreeSurfer) with respect to a reference region. In amyloid and tau imaging, SUVR is typically generated using some portion or the entire cerebellum as a reference because cerebellum is not affected until late in the progression of AD.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.021" spread="0.0072"/>
                    <measurement group_id="O2" value="-0.030" spread="0.0083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.047" spread="0.0063"/>
                    <measurement group_id="O2" value="-0.043" spread="0.0074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.074" spread="0.0110"/>
                    <measurement group_id="O2" value="-0.074" spread="0.0127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.967</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.001</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0168</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.034</ci_lower_limit>
            <ci_upper_limit>0.033</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Imaging Measures- Brain Atrophy as Measured by Cortical Thickness of Regions of Interest - Precuneus Region</title>
        <description>Brain atrophy was defined by structural magnetic resonance imaging (MRI) A Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequence was processed using the Freesurfer software suite. This package provides volumes and thickness values for cortical regions and volumes for subcortical regions. For the clinical trial we examined cortical thickness values in prespecified regions of interest known to show atrophy in autosomal dominant Alzheimer Disease. Higher measurements are more favorable.</description>
        <time_frame>Baseline and Weeks 52, 104, 156 and 208</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Imaging Measures- Brain Atrophy as Measured by Cortical Thickness of Regions of Interest - Precuneus Region</title>
          <description>Brain atrophy was defined by structural magnetic resonance imaging (MRI) A Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequence was processed using the Freesurfer software suite. This package provides volumes and thickness values for cortical regions and volumes for subcortical regions. For the clinical trial we examined cortical thickness values in prespecified regions of interest known to show atrophy in autosomal dominant Alzheimer Disease. Higher measurements are more favorable.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>Millimeters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.033" spread="0.0106"/>
                    <measurement group_id="O2" value="-0.053" spread="0.0114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.067" spread="0.0142"/>
                    <measurement group_id="O2" value="-0.090" spread="0.0156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.110" spread="0.0193"/>
                    <measurement group_id="O2" value="-0.122" spread="0.0214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.138" spread="0.0254"/>
                    <measurement group_id="O2" value="-0.154" spread="0.0279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.669</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.016</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0377</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.059</ci_lower_limit>
            <ci_upper_limit>0.092</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Imaging Measures- Volumetric MRI Combined Total Volume Corrected for Head Size - Hippocampus Volume</title>
        <description>Brain atrophy was defined by structural magnetic resonance imaging (MRI) A Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequence was processed using the Freesurfer software suite. This package provides volumes and thickness values for cortical regions and volumes for subcortical regions. For the clinical trial we examined volume values in prespecified regions of interest known to show atrophy in autosomal dominant Alzheimer Disease.</description>
        <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Imaging Measures- Volumetric MRI Combined Total Volume Corrected for Head Size - Hippocampus Volume</title>
          <description>Brain atrophy was defined by structural magnetic resonance imaging (MRI) A Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequence was processed using the Freesurfer software suite. This package provides volumes and thickness values for cortical regions and volumes for subcortical regions. For the clinical trial we examined volume values in prespecified regions of interest known to show atrophy in autosomal dominant Alzheimer Disease.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>Cubic Millimeters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-106.74" spread="71.081"/>
                    <measurement group_id="O2" value="-153.34" spread="78.529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-341.35" spread="72.549"/>
                    <measurement group_id="O2" value="-302.58" spread="80.556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-524.14" spread="76.210"/>
                    <measurement group_id="O2" value="-541.76" spread="84.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-706.41" spread="78.746"/>
                    <measurement group_id="O2" value="-671.95" spread="85.672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-977.91" spread="116.633"/>
                    <measurement group_id="O2" value="-551.42" spread="137.366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.768</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-34.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>116.419</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-264.14</ci_lower_limit>
            <ci_upper_limit>195.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Imaging Measures- Brain Tau Load as Measured by Flortaucipir PET Non-partial Volume Corrected</title>
        <description>This variable represents how much neurofibrillary tau pathology is present in brain as assessed using positron emission tomography (PET). Scans were conducted using [F18] Flortaucipir, a commonly used tracer in the field.</description>
        <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end). In addition, the tau tracer was not introduced in the trial until after baseline for most participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Imaging Measures- Brain Tau Load as Measured by Flortaucipir PET Non-partial Volume Corrected</title>
          <description>This variable represents how much neurofibrillary tau pathology is present in brain as assessed using positron emission tomography (PET). Scans were conducted using [F18] Flortaucipir, a commonly used tracer in the field.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end). In addition, the tau tracer was not introduced in the trial until after baseline for most participants.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77391" spread="0.548324"/>
                    <measurement group_id="O2" value="1.52502" spread="0.582485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46020" spread="0.503595"/>
                    <measurement group_id="O2" value="1.49041" spread="0.434475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Baseline in Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11302" spread="0.221413"/>
                    <measurement group_id="O2" value="-0.03925" spread="0.192448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49990" spread="0.506423"/>
                    <measurement group_id="O2" value="1.42231" spread="0.394000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15450" spread="0.252682"/>
                    <measurement group_id="O2" value="0.01208" spread="0.263170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43263" spread="0.402563"/>
                    <measurement group_id="O2" value="1.28081" spread="0.295191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05275" spread="0.052679"/>
                    <measurement group_id="O2" value="0.05825" spread="0.023688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Imaging Measures- Brain Atrophy as Measured by Whole Brain Volume Corrected for Head Size</title>
        <description>Brain atrophy was defined by structural magnetic resonance imaging (MRI) A Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequence was processed using the Freesurfer software suite. This package provides volumes and thickness values for cortical regions and volumes for subcortical regions. A whole brain volume measure was generated to represent global atrophy across the cortical and subcortical regions.</description>
        <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Imaging Measures- Brain Atrophy as Measured by Whole Brain Volume Corrected for Head Size</title>
          <description>Brain atrophy was defined by structural magnetic resonance imaging (MRI) A Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequence was processed using the Freesurfer software suite. This package provides volumes and thickness values for cortical regions and volumes for subcortical regions. A whole brain volume measure was generated to represent global atrophy across the cortical and subcortical regions.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>Cubic Millimeters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11990.31" spread="4027.589"/>
                    <measurement group_id="O2" value="-10578.56" spread="4409.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19808.05" spread="4106.838"/>
                    <measurement group_id="O2" value="-22147.27" spread="4524.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32713.22" spread="4304.849"/>
                    <measurement group_id="O2" value="-30590.95" spread="4770.402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39306.90" spread="4446.803"/>
                    <measurement group_id="O2" value="-36569.28" spread="4816.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54558.23" spread="6562.583"/>
                    <measurement group_id="O2" value="-50077.53" spread="7713.907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.677</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2737.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6558.467</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15678.06</ci_lower_limit>
            <ci_upper_limit>10202.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Imaging Measures- Brain Atrophy as Measured by Ventricular Volume (Volumetric MRI) Corrected for Head Size</title>
        <description>Rather than looking at how tissue in the brain changes, it is also possible to quantify how the ventricles, fluid filled spaces in the brain, change. Increasing ventricular volume represents greater amounts of cerebral spinal fluid which suggests atrophy of the brain. Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequences were processed using the Freesurfer software suite. Total ventricular volume was calculated from the ventricular volumes generated by this program.</description>
        <time_frame>Baseline and Weeks 52, 104, 156, 208 and 260</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Imaging Measures- Brain Atrophy as Measured by Ventricular Volume (Volumetric MRI) Corrected for Head Size</title>
          <description>Rather than looking at how tissue in the brain changes, it is also possible to quantify how the ventricles, fluid filled spaces in the brain, change. Increasing ventricular volume represents greater amounts of cerebral spinal fluid which suggests atrophy of the brain. Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequences were processed using the Freesurfer software suite. Total ventricular volume was calculated from the ventricular volumes generated by this program.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>Cubic Millimeters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1815.99" spread="1067.526"/>
                    <measurement group_id="O2" value="1796.78" spread="1182.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2972.85" spread="1094.409"/>
                    <measurement group_id="O2" value="4452.69" spread="1218.440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5705.59" spread="1163.978"/>
                    <measurement group_id="O2" value="6729.64" spread="1297.406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8755.04" spread="1212.184"/>
                    <measurement group_id="O2" value="9833.37" spread="1312.937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12332.3" spread="1907.752"/>
                    <measurement group_id="O2" value="11456.61" spread="2258.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.547</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1078.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1788.474</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4603.28</ci_lower_limit>
            <ci_upper_limit>2446.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Fluid Biomarker Measures- CSF Aβ 40 Free Change From Baseline</title>
        <description>Measured concentration of the drug bound and free soluble Aβ1-40 peptide in cerebrospinal fluid using enzyme-linked immunosorbent assay (ELISA)</description>
        <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Solanezumab Direct Placebo</title>
            <description>Subjects enrolled under solanezumab placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Fluid Biomarker Measures- CSF Aβ 40 Free Change From Baseline</title>
          <description>Measured concentration of the drug bound and free soluble Aβ1-40 peptide in cerebrospinal fluid using enzyme-linked immunosorbent assay (ELISA)</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1613.48" spread="185.134"/>
                    <measurement group_id="O2" value="-856.65" spread="284.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2237.73" spread="177.616"/>
                    <measurement group_id="O2" value="-1398.13" spread="290.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2567.13" spread="229.807"/>
                    <measurement group_id="O2" value="-631.22" spread="307.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1935.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>385.538</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2717.64</ci_lower_limit>
            <ci_upper_limit>-1154.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Fluid Biomarker Measures- CSF Aβ 42 Free</title>
        <description>Measured concentration of the total soluble Aβ 1-42 peptide in cerebrospinal fluid using ELISA</description>
        <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Solanezumab Direct Placebo</title>
            <description>Subjects enrolled under solanezumab placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Fluid Biomarker Measures- CSF Aβ 42 Free</title>
          <description>Measured concentration of the total soluble Aβ 1-42 peptide in cerebrospinal fluid using ELISA</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-109.33" spread="24.235"/>
                    <measurement group_id="O2" value="-79.35" spread="37.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-172.55" spread="14.535"/>
                    <measurement group_id="O2" value="-125.64" spread="24.402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-250.78" spread="13.935"/>
                    <measurement group_id="O2" value="-173.66" spread="18.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-77.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>23.014</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-124.56</ci_lower_limit>
            <ci_upper_limit>-29.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Fluid Biomarker Measures- CSF Tau</title>
        <description>Measured concentration of the soluble Tau peptide in cerebrospinal fluid</description>
        <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data was not collected for all participants at each time point for various reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Fluid Biomarker Measures- CSF Tau</title>
          <description>Measured concentration of the soluble Tau peptide in cerebrospinal fluid</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data was not collected for all participants at each time point for various reasons</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.73" spread="14.884"/>
                    <measurement group_id="O2" value="-6.60" spread="15.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.74" spread="15.649"/>
                    <measurement group_id="O2" value="23.24" spread="16.783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.08" spread="24.691"/>
                    <measurement group_id="O2" value="28.19" spread="25.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.388</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>30.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>35.540</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.04</ci_lower_limit>
            <ci_upper_limit>101.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Fluid Biomarker Measures- CSF pTau 181</title>
        <description>Measured concentration of phosphorylated tau at threonine-181 in cerebrospinal fluid</description>
        <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data was not collected for all participants at each time point for various reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Fluid Biomarker Measures- CSF pTau 181</title>
          <description>Measured concentration of phosphorylated tau at threonine-181 in cerebrospinal fluid</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data was not collected for all participants at each time point for various reasons</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="2.951"/>
                    <measurement group_id="O2" value="-0.18" spread="3.254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.91" spread="2.903"/>
                    <measurement group_id="O2" value="4.25" spread="3.290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.90" spread="4.447"/>
                    <measurement group_id="O2" value="7.65" spread="4.907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.909</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.624</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.97</ci_lower_limit>
            <ci_upper_limit>12.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Change From Baseline Fluid Biomarker Measures- CSF Neurofilament Light Chain (NfL)</title>
        <description>Measured concentration of neurofilament light chain in cerebrospinal fluid using SIMO</description>
        <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Change From Baseline Fluid Biomarker Measures- CSF Neurofilament Light Chain (NfL)</title>
          <description>Measured concentration of neurofilament light chain in cerebrospinal fluid using SIMO</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.102" spread="0.0414"/>
                    <measurement group_id="O2" value="0.144" spread="0.0463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.191" spread="0.0314"/>
                    <measurement group_id="O2" value="0.159" spread="0.0354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.426" spread="0.0402"/>
                    <measurement group_id="O2" value="0.248" spread="0.0435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.004</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.178</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0593</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.059</ci_lower_limit>
            <ci_upper_limit>0.296</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Fluid Biomarker Measures- Plasma Neurofilament Light Chain (NfL)</title>
        <description>Measured concentration of neurofilamnet light chain in plasma using Single Molecule Array (SIMOA)</description>
        <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data was not collected for all participants at each time point for various reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Fluid Biomarker Measures- Plasma Neurofilament Light Chain (NfL)</title>
          <description>Measured concentration of neurofilamnet light chain in plasma using Single Molecule Array (SIMOA)</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data was not collected for all participants at each time point for various reasons</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="1.864"/>
                    <measurement group_id="O2" value="4.03" spread="1.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="0.799"/>
                    <measurement group_id="O2" value="3.15" spread="0.780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.29" spread="0.959"/>
                    <measurement group_id="O2" value="3.72" spread="0.960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>0.754</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.355</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.21</ci_lower_limit>
            <ci_upper_limit>2.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Fluid Biomarker Measures- Plasma Anti-drug Antibodies (ADA)</title>
        <description>Measurement of the presence or absence of anti-drug antibodies in serum&#xD;
Note: Mutation Negative Placebo subjects are not displayed as anti-drug antibody testing was not to be evaluated for these subjects.&#xD;
Note: Treatment Emergent Anti-Drug Antibody Positive subjects are defined as those with either (a) a baseline status of ADA Not Present and at least one post-baseline ADA present with a titer &gt;= 1:20 or (b) both a baseline and post-baseline status of ADA Present with the post-baseline titer being 2 dilutions (4-fold) greater than the baseline titer.&#xD;
Note: Treatment Emergent Anti-Drug Antibody Inconclusive subjects are defined as those for whom &gt;=20% of the subject's post-baseline ADA results are ADA Inconclusive and all remaining post-baseline samples are ADA Not Present.&#xD;
Note: Treatment Emergent Anti-Drug Antibody Negative subjects are defined as those who are evaluable for TE ADA but are neither TE ADA Positive nor TE ADA Inconclusive.</description>
        <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Mutation Positive Placebos</title>
            <description>Mutation positive placebos enrolled under each arm but pooled for result reporting.</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Fluid Biomarker Measures- Plasma Anti-drug Antibodies (ADA)</title>
          <description>Measurement of the presence or absence of anti-drug antibodies in serum&#xD;
Note: Mutation Negative Placebo subjects are not displayed as anti-drug antibody testing was not to be evaluated for these subjects.&#xD;
Note: Treatment Emergent Anti-Drug Antibody Positive subjects are defined as those with either (a) a baseline status of ADA Not Present and at least one post-baseline ADA present with a titer &gt;= 1:20 or (b) both a baseline and post-baseline status of ADA Present with the post-baseline titer being 2 dilutions (4-fold) greater than the baseline titer.&#xD;
Note: Treatment Emergent Anti-Drug Antibody Inconclusive subjects are defined as those for whom &gt;=20% of the subject's post-baseline ADA results are ADA Inconclusive and all remaining post-baseline samples are ADA Not Present.&#xD;
Note: Treatment Emergent Anti-Drug Antibody Negative subjects are defined as those who are evaluable for TE ADA but are neither TE ADA Positive nor TE ADA Inconclusive.</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline : Not Detected</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline : Detected</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Detected Titer 1:10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Detected Titer 1:20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 : Not Detected</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 : Detected</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 : Detected Titer 1:10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 : Detected Titer 1:20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 : Detected Titer 1:80</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 : Not Detected</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 : Detected</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 : Detected Titer 1:10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 : Detected Titer 1:20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 : Detected Titer 1:80</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 : Detected Titer 1:320</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208 : Not Detected</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208 : Detected</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208 : Detected Titer 1:10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208 : Detected Titer 1:20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Emergent ADA Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=1 Positive Neutralizing Antibody Result</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Emergent ADA Inconclusive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Emergent ADA Negative</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Fluid Biomarker Measures- Total Plasma Aβ 1-40</title>
        <description>Measured concentration of the total soluble Aβ 1-40 peptide in cerebrospinal fluid using ELISA</description>
        <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data was not collected for all participants at each time point for various reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Solanezumab Direct Placebo</title>
            <description>Subjects enrolled under solanezumab placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Fluid Biomarker Measures- Total Plasma Aβ 1-40</title>
          <description>Measured concentration of the total soluble Aβ 1-40 peptide in cerebrospinal fluid using ELISA</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data was not collected for all participants at each time point for various reasons</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168588.48" spread="5889.151"/>
                    <measurement group_id="O2" value="-9257.53" spread="9091.376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165220.34" spread="5425.379"/>
                    <measurement group_id="O2" value="-9263.35" spread="9010.529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220136.05" spread="8168.936"/>
                    <measurement group_id="O2" value="-9226.25" spread="12358.817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>229362.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14863.080</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>199264.32</ci_lower_limit>
            <ci_upper_limit>259460.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Fluid Biomarker Measures- Total Plasma Aβ 42</title>
        <description>Measured concentration of the total soluble Aβ 1-42 peptide in cerebrospinal fluid using ELISA</description>
        <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Solanezumab Direct Placebo</title>
            <description>Subjects enrolled under solanezumab placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Fluid Biomarker Measures- Total Plasma Aβ 42</title>
          <description>Measured concentration of the total soluble Aβ 1-42 peptide in cerebrospinal fluid using ELISA</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30609.39" spread="1555.170"/>
                    <measurement group_id="O2" value="526.91" spread="2334.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29265.35" spread="1459.112"/>
                    <measurement group_id="O2" value="746.90" spread="2424.659"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33744.89" spread="922.711"/>
                    <measurement group_id="O2" value="838.29" spread="1415.925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>32906.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1697.541</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29406.49</ci_lower_limit>
            <ci_upper_limit>36406.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Fluid Biomarker Measures- CSF Aβ 42 Total</title>
        <description>Measured concentration of the total soluble Aβ1-42 peptide in cerebrospinal fluid using enzyme-linked immunosorbent assay (ELISA)</description>
        <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Solanezumab Direct Placebo</title>
            <description>Subjects enrolled under solanezumab placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Fluid Biomarker Measures- CSF Aβ 42 Total</title>
          <description>Measured concentration of the total soluble Aβ1-42 peptide in cerebrospinal fluid using enzyme-linked immunosorbent assay (ELISA)</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="558.91" spread="44.533"/>
                    <measurement group_id="O2" value="44.81" spread="69.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="623.16" spread="41.301"/>
                    <measurement group_id="O2" value="89.32" spread="68.119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1352.83" spread="75.447"/>
                    <measurement group_id="O2" value="66.48" spread="118.662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1286.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>140.692</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1002.79</ci_lower_limit>
            <ci_upper_limit>1569.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solanezumab: Fluid Biomarker Measures- CSF Aβ 40 Total</title>
        <description>Measured concentration of the total soluble Aβ1-40 peptide in cerebrospinal fluid using enzyme-linked immunosorbent assay (ELISA)</description>
        <time_frame>Baseline and Weeks 52, 104 and 208</time_frame>
        <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
        <group_list>
          <group group_id="O1">
            <title>Solanezumab</title>
            <description>Solanezumab: Intravenous infusion every 4 weeks at escalating doses</description>
          </group>
          <group group_id="O2">
            <title>Solanezumab Direct Placebo</title>
            <description>Subjects enrolled under solanezumab placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Solanezumab: Fluid Biomarker Measures- CSF Aβ 40 Total</title>
          <description>Measured concentration of the total soluble Aβ1-40 peptide in cerebrospinal fluid using enzyme-linked immunosorbent assay (ELISA)</description>
          <population>Number analyzed represents actual data collections at each collection time point. Data unavailable at any time point was not collected for various reasons i.e. participant attrition or common close design (participants did not reach that time point before trial end).</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3676.97" spread="403.908"/>
                    <measurement group_id="O2" value="-414.57" spread="625.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4017.93" spread="331.917"/>
                    <measurement group_id="O2" value="-594.08" spread="549.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9723.95" spread="669.037"/>
                    <measurement group_id="O2" value="-143.31" spread="1011.672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test of equality (any treatment difference)</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9867.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1212.232</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7419.38</ci_lower_limit>
            <ci_upper_limit>12315.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE data was collected from consenting up to post study follow-up 8-12 weeks after last dose, approximately 6 years overall.</time_frame>
      <desc>In order to protect the genetic blinding requested by participants, as well as treatment assignment in the double-blind period to protect integrity of the ongoing open-label extension, the following precautions have been taken: 1) All Other (Not Including Serious) AEs have been reported by the higher level SOC; 2) SAEs have been summarized per arm at the general organ system level, and additionally at the subject level using a combined Arm/Group necessary to preserve participant confidentiality</desc>
      <group_list>
        <group group_id="E1">
          <title>Gantenerumab</title>
          <description>Gantenerumab Active Treatment: Dosing subcutaneously every 4 weeks at escalating doses</description>
        </group>
        <group group_id="E2">
          <title>Solanezumab</title>
          <description>Solanezumab Active Treatment: Dosing by intravenous infusion every 4 weeks at escalating doses</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>All placebos including mutation negative and positive</description>
        </group>
        <group group_id="E4">
          <title>DIAN OBS Control Group</title>
          <description>Participants in the DIAN-OBS study who met DIAN-TU inclusion criteria were used as natural history controls for improved estimates of the placebo group.&#xD;
DIAN-OBS participants were included based on specific criteria as outlined in the SAP; included at the first visit where eligibility was met which means their period of eligibility would not match the full period of time as the DIAN-TU-001 placebo participants.</description>
        </group>
        <group group_id="E5">
          <title>Combined Blinded</title>
          <description>All arms/groups combined for the purpose of maintaining blinding for participant mutation status and treatment group.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>To maintain blinding to participants' genetic status and assigned treatment, SAEs reported at the arm/group level are included under the General disorders SOC; all other SOCs are reported in the Combined Blinded Group.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders</sub_title>
                <description>To maintain blinding to participants' genetic status and assigned treatment, SAEs reported at the arm/group level are included under the General disorders SOC; all other SOCs are reported in the Combined Blinded Group.</description>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E3" events="23" subjects_affected="12" subjects_at_risk="89"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>General disorders</sub_title>
                <description>To maintain blinding to participants' genetic status and assigned treatment, SAEs reported at the arm/group level are included under the General disorders SOC; all other SOCs are reported in the Combined Blinded Group.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <description>To maintain blinding to participants' genetic status and assigned treatment, SAEs reported at the arm/group level are included under the General disorders SOC; all other SOCs are reported in the Combined Blinded Group.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <description>To maintain blinding to participants' genetic status and assigned treatment, SAEs reported at the arm/group level are included under the General disorders SOC; all other SOCs are reported in the Combined Blinded Group.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="16" subjects_affected="14" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <description>To maintain blinding to participants' genetic status and assigned treatment, SAEs reported at the arm/group level are included under the General disorders SOC; all other SOCs are reported in the Combined Blinded Group.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified</sub_title>
                <description>To maintain blinding to participants' genetic status and assigned treatment, SAEs reported at the arm/group level are included under the General disorders SOC; all other SOCs are reported in the Combined Blinded Group.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <description>To maintain blinding to participants' genetic status and assigned treatment, SAEs reported at the arm/group level are included under the General disorders SOC; all other SOCs are reported in the Combined Blinded Group.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="12" subjects_affected="11" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <description>To maintain blinding to participants' genetic status and assigned treatment, SAEs reported at the arm/group level are included under the General disorders SOC; all other SOCs are reported in the Combined Blinded Group.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <description>To maintain blinding to participants' genetic status and assigned treatment, SAEs reported at the arm/group level are included under the General disorders SOC; all other SOCs are reported in the Combined Blinded Group.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders</sub_title>
                <description>To maintain blinding to participants' genetic status and assigned treatment, SAEs reported at the arm/group level are included under the General disorders SOC; all other SOCs are reported in the Combined Blinded Group.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <description>To maintain blinding to participants' genetic status and assigned treatment, SAEs reported at the arm/group level are included under the General disorders SOC; all other SOCs are reported in the Combined Blinded Group.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <description>To maintain blinding to participants' genetic status and assigned treatment, SAEs reported at the arm/group level are included under the General disorders SOC; all other SOCs are reported in the Combined Blinded Group.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="262"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="89" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E3" events="17" subjects_affected="11" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Disorders</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="115" subjects_affected="33" subjects_at_risk="52"/>
                <counts group_id="E2" events="88" subjects_affected="35" subjects_at_risk="52"/>
                <counts group_id="E3" events="133" subjects_affected="48" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="1066" subjects_affected="50" subjects_at_risk="52"/>
                <counts group_id="E2" events="70" subjects_affected="31" subjects_at_risk="52"/>
                <counts group_id="E3" events="262" subjects_affected="54" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="180" subjects_affected="39" subjects_at_risk="52"/>
                <counts group_id="E2" events="170" subjects_affected="41" subjects_at_risk="52"/>
                <counts group_id="E3" events="223" subjects_affected="62" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="92" subjects_affected="36" subjects_at_risk="52"/>
                <counts group_id="E2" events="85" subjects_affected="35" subjects_at_risk="52"/>
                <counts group_id="E3" events="146" subjects_affected="52" subjects_at_risk="89"/>
                <counts group_id="E4" events="35" subjects_affected="27" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="31" subjects_affected="16" subjects_at_risk="52"/>
                <counts group_id="E2" events="19" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E3" events="55" subjects_affected="30" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E3" events="17" subjects_affected="14" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="95" subjects_affected="30" subjects_at_risk="52"/>
                <counts group_id="E2" events="89" subjects_affected="28" subjects_at_risk="52"/>
                <counts group_id="E3" events="140" subjects_affected="52" subjects_at_risk="89"/>
                <counts group_id="E4" events="38" subjects_affected="25" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="192" subjects_affected="41" subjects_at_risk="52"/>
                <counts group_id="E2" events="175" subjects_affected="38" subjects_at_risk="52"/>
                <counts group_id="E3" events="276" subjects_affected="58" subjects_at_risk="89"/>
                <counts group_id="E4" events="48" subjects_affected="30" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="55" subjects_affected="22" subjects_at_risk="52"/>
                <counts group_id="E2" events="51" subjects_affected="29" subjects_at_risk="52"/>
                <counts group_id="E3" events="50" subjects_affected="29" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="54" subjects_affected="24" subjects_at_risk="52"/>
                <counts group_id="E2" events="64" subjects_affected="22" subjects_at_risk="52"/>
                <counts group_id="E3" events="91" subjects_affected="33" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="52" subjects_affected="23" subjects_at_risk="52"/>
                <counts group_id="E2" events="36" subjects_affected="18" subjects_at_risk="52"/>
                <counts group_id="E3" events="49" subjects_affected="29" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Social Circumstances</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <description>In order to maintain blinding to participants' genetic status and assigned treatment, this AE is reported by system organ class.</description>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E3" events="18" subjects_affected="13" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E5" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI's may publish data and study results individually after the earlier of: 1) multi-center Publication is published; 2) no multi-center publication is submitted within 18 months after conclusion, abandonment, or termination of the Protocol at all sites; or 3) sponsor confirms in writing there will be no multi-center Publication. PI must submit results communications to the sponsor at least 75 days prior to submission or presentation. Sponsor can require changes to the communication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Administrative Director</name_or_title>
      <organization>Washington University</organization>
      <phone>(314) 221-8344</phone>
      <email>DIAN-TUDataRequest@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

